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Infiltrative morphological mimicry at sites of biopsy-proven nodular basal cell 
carcinoma has been described. The immunoprofile of scar BCCs (scar BCCs, 
SBCCs) has not been documented. The aim of this study was to assess the 
histopathological spectrum, stromal (fibronectin, laminin, actin, desmin and 
vimentin) response and proliferation (bcl-2, MIB1 and p53) status of SBCCs. 
Twenty nine BCCs occurring in scars, unrelated to previous malignancy (de 
novo scar BCCS, DN-SBCCs), 27 BCCs that were incompletely excised and 
regrew at the same site (regrowth scar BCCs, RG-SBCCs) and 25 BCCs that 
were completely excised with tumour free margins, but recurred at the same 
site (recurrent scar BCCs, R-SBCCs) were accessed from the files of the 
Department of Pathology and Plastic and Reconstructive Surgery of the 
Faculty of Medicine, University of KwaZulu Natal, and formed the basis of this 
study. 
The morphological features of DN-SBCCs was pure (3%), predominantly 
nodular (79%), micronodular (7%) and infiltrative (11 %). RG-SBCCs were 
predominantly nodular (82%), micronodular (7%) and infiltrative (11%). R-
SBCCs were predominantly nodular (80%), micronodular (4%) and infiltrative 
(16%). 
The majority of DN-SBCCs, RG-SBCCs and R-SBCCs showed intact 
basement membrane laminin staining, while two (7%) DN-SBCCs showed 1 + 
and 2+ loss of basement membrane laminin staining. Three (11 %) and two 
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(8%) RG-SBCCs and R-SBCCs, respectively, showed 2+ or 3+ basement 
membrane laminin discontinuity. The majority of DN-SBCCs (83%), RG-
SBCCs (75%) and R-SBCCs (88%) were actin negative. No desmin 
immunopositivity was demonstrated in the epithelial or stromal components of 
DN-SBCCs, RG-SBCCs and R-SBCCs. All BCC groups showed high 3+ or 
4+ vimentin immunopositivity. The majority (>50%) of the SBCCs showed low 
(<2+) fibronectin immunopositivity. DN-SBCCs and R-SBCCs showed low 
(<2+) fibronectin immunopositivity in 76%, while 52% of RG-SBCCs showed 
low (^2+) fibronectin immunopositivity. MIB1 immunostaining revealed a 
range, but no significant trend of proliferative activity in all cell groups. The 
majority (77%) of the SBCCs showed high (>2+) bcl-2 immunopositivity. 
There was no significant difference in p53 immunopositivity in all SBCCs. 
SBCCs demonstrate phenotypic and immunophenotypic heterogeneity. That 
DN-SBCCs with the infiltrative and micronodular patterns have not recurred 
implies that the histomorphology is a pseudo-aggressive pattern. A similar 
view could pertain to RG-SBCCs, but because the scar did not cicatrise the 
incompletely excised BCC implies that the histomorphology of RG-BCC may 
be a potentially more aggressive phenotype. The recurrence of a completely 
excised basal cell carcinoma may be viewed as a feature of an aggressive 
tumour, especially when the recurrent BCC contains micronodular and 
infiltrative components. However, as most R-SBCCs occurred at head and 
neck sites that are exposed to ultraviolet light, it is also possible that these are 
simply new BCCs occurring within scars in head and neck sites prone to 
BCCs. Furthermore, these R-SBCCs were not destructive tumours. 
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CONCLUSION: 
None of the infiltrative foci of DN-SBCCs demonstrated laminin loss. Three of 
5 with intra-epithelial actin immunopositivity also demonstrated low bcl-2 and 
high p53 staining, immunoprofiling these with an aggressive infiltrative 
component. 
Of 11 RG-SBCCs with high p53 staining, 4 had high p53 staining in the 
infiltrative component, but only one had a low bcl-2 composite score and low 
bcl-2 score in the infiltrative focus. In addition, these infiltrative foci 
demonstrated intraepithelial MSA positivity and a "VA" immunophenotype of 
the stromal cells, indicating one RG-SBCC with an established, aggressive 
immunophenotype. Those positive with one or more, but not all, aggressive 
immunostains, are hypothesised to be RG-SBCCs evolving/developing an 
aggressive immunophenotype. 
Only one R-SBCC, with a predominantly infiltrative pattern, had a "full-house" 
of aggressive immunostaining in the infiltrative foci: low bcl-2, high p53, 2+ 
laminin discontinuity and intra-epithelial and stromal MSA positivity. Of 
significance is that 7 with a predominant nodular pattern had a high p53 
score. Of these, 5 had high bcl-2 scores. Hence, while high p53 may be a 
feature of aggressive growth, it is important that this staining be 
complemented with that of bcl-2, laminin and MSA. 
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> 60% of the growth patterns are nodular 
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> 60% of the growth patterns are infiltrative 
Papillary dermis and upper half of reticular 
dermis 
Lower half of reticular dermis 
BCCs that arise in areas of scarring from 
various causes, which include burns, 
trauma, vaccination, tattooing, chicken pox 
and leg ulcers 
BCCs that have been incompletely excised 
and have regrown at the same site 
BCCs that have been completely excised 
with tumour free margins, but recurred at 
the same site 
MSA Muscle specific actin 
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CHAPTER 1 2 
1.1 INTRODUCTION 
BCC is a "low grade malignant epithelial neoplasm composed of cells 
simulating the basal cell layer of the epidermis" (Heenan et al, 1996). It is the 
most common type of skin cancer in the world. They are seen commonly on 
hair bearing skin, especially on the face and neck. Most BCCs are 
characterized by indolent clinical growth and a recurrence rate of 10-40%, 
depending on the mode of therapy employed (Horlock etal, 1998). A minority 
of BCCs, however, display abberant, destructive behaviour and have been 
labeled aggressive, mutilating, giant or horrifying BCCs. BCCs can be 
subtyped according to their clinical appearance and histological features. 
Identification of these features may give the clinician an idea of the prognosis 
and growth pattern of the tumour. A range of non-aggressive and aggressive 
histological subtypes of BCCs have been described (Lever, 1990; Lang and 
Maize, 1986; Sloane, 1977). The former includes superficial and nodular 
subtypes while the latter encompasses morphoeic, sclerosing, desmoplastic, 
micronodular and infiltrative subtypes. Aggressive and non-aggressive BCC 
subtypes differ, not only in terms of histopathological profile, but also by the 
immunohistochemical stromal and proliferation profile. A group of workers 
documented aggressive infiltrative histopathological mimicry at sites of 
biopsy-proven nodular BCC, a histologically non-aggressive subtype (Swetter 
et al, 1998). The immunoprofile of this cohort of tumours was not assessed. 
Apart from this report, there is no documentation on the proliferation status or 
stromal (basement membrane and stromal cellular and matrix) features of 
BCCs occurring in scars (scar BCCs). 
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Scar BCCs arise in scars induced by burns, trauma, vaccination, tattoos, 
chickenpox, leg ulcers or following cardiac surgery (Koga and Sawada, 1997; 
Kulwin, 1975; Hendricks, 1980; Dolan, 1998). BCCs may also regrow at scar 
sites of previously incompletely excised BCCs (Richmond and Davie, 1987). 
Scarring can cause changes in the connective tissue stroma that may play a 
role in subsequent BCC growth. The Veterans Affairs Palo Alto Health Care 
System [VAPAHCS] has reported that a focal infiltrative pattern developed in 
the region of biopsy scars in re-excision specimens of a number of their cases 
which were examined histopathologically over a 2 year period (Swetter et at, 
1998). The initial biopsies were diagnosed clinically and histologically as 
nodular BCC. The VAPAHCS also stated that they could not exclude the 
possibility that focal infiltrative changes were present in the original nodular 
BCCs [ie. mixed pattern tumours], but the presence of fibrosis and a foreign 
body reaction adjacent to the infiltrative changes in the re-excision specimens 
supported the concept that focally infiltrative BCC was induced by the biopsy 
procedure and scar formation. 
This study therefore seeks to evaluate the histopathological spectrum of all 
scar BCCs. Because infiltrative aggressive BCCs are characterized by 
alterations in the proliferation marker status, a need exists to determine 
whether the infiltrative BCCs in scar tissue that mimic aggressive infiltrative 
BCCs histologically, also share the aggressive proliferation status of the 
aggressive infiltrative tumours. Because BCCs have a well-known 
interdependence with the adjacent mesenchyme, it is undocumented whether 
the basement membrane and stromal cellular and matrix characteristics of the 
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surrounding scar tissue, at an immunohistochemical level, mimic that of the 
non-aggressive or aggressive BCC subtypes. This study therefore aims to 
assess whether the scar BCCs mimic aggressive infiltrative BCCs at an 
immunohistochemical level as well, or, whether immunohistochemical 
markers can differentiate between scar-induced infiltrative "pseudo-
aggressive" tumours and those that are de novo infiltrative and aggressive. 
1.2 OBJECTIVES 
1.1.1 To assess the histopathological spectrum of scar BCCs. 
1.1.2 To assess the stromal response in scar BCCs. 
1.1.3 To assess the proliferation status of scar BCCs. 
CHAPTER 2 
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2.0 BACKGROUND AND LITERATURE REVIEW 
2.1 CLINICAL AND HISTOPATHOLOGICAL ASPECTS 
2.1.1 BCCs: GENERAL 
BCCs are the commonest of all malignant skin tumours that can be treated in 
several different ways, including surgical excision, curettage and 
electrodessication, radiotherapy, cryotherapy and Moh's surgery (Lauritzen et 
al, 1965). Arthur Jacob, an Irish ophthalmologist, was the first to give a 
description of "extensive rodent ulcers" in the face of 3 patients (Jacob, 1827). 
Cecil Beadles described the first "metastatic rodent ulcer". He reported 
metastases from a primary lesion on the face to a submandibular lymph node 
(Beadles, 1894). In his description, the histology of metastatic BCC was 
described for the first time. In 1897, BCC was described in Hyde and 
Montgomery's textbook on diseases of the skin as "superficial epithelioma" 
(Ramdial, MMed Thesis, University of KwaZulu-Natal, 1999). In their text, the 
BCC was described clinically as "rodent ulcer" and histologically as "tubular 
epithelioma". Krompecher, for the first time in 1903, described in detail, the 
histological appearance of BCCs (Lever and Schaumburg-Lever, 1990). He 
also recognized that the BCCs originated in the basal layer of the epidermis 
and epidermal appendages as none of the other cell types were seen in a 
typical rodent ulcer. 
In 1910 and 1912, MacCormacand Korbi, in independent studies, recognised 
tumours that were intermediate between that of a BCC and squamous cell 
carcinoma (MacCormac, 1910; Borel, 1973). 
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In 1928, Montgomery felt that these tumours were morphologically similar to 
BCCs but behaviourally identical to squamous cell carcinoma and referred to 
them as "basal squamous cell epithelioma". Foot (1947) classified these 
basal cell tumours into pilar, sudorific and primordial, based on resemblances 
to the hair follicle, the sweat gland, and the "primordium", a common stage 
through which both of these structures pass in development. 
In 1951, Lennox and Wells discussed differentiation within the "rodent ulcer 
group of tumours". They collected a series of rodent ulcers, classified them 
according to Foot's (1947) criteria, and then applied to them all available 
clinical behaviour in the hope of separating them, but unfortunately this was 
not possible. Their forms of differentiation after analysis were: presence or 
absence of melanin pigment, palisade formation, fluid formation and whorl 
formation. Thackray (1951) attempted to classify rodent ulcers histologically 
and found that the only method of dividing the tumours which seemed to bear 
any relationship to prognosis, was that based on the growth pattern, into 
circumscribed or infiltrative. The fact that an intermediate group was 
necessary indicates the difficulty in making this distinction. Similar views were 
expressed by Lever (1948), who stated that the appearances usually 
interpreted as baso-squamous cell carcinoma were simply areas of 
keratinisation in basal-cell carcinomas and were of no prognostic significance. 
Burston and Clay (1959) stated that tumours with separate basal cell and 
squamous components should be detailed as such. The tumours with benign 
keratinisation were in fact keratotic BCCs, and that basosquamous 
carcinomas were simply areas of keratinisation in BCCs and were of no 
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prognostic significance. At the turn of this decade, a form of BCC with the 
clinical behaviour and histology different to that of a rodent ulcer was still a 
controversial issue, and, although debate on the cell of origin continued, very 
little new information was added to the world literature on the subject. 
A large number of reports on metastatic BCCs were documented in the 
sixties. In 1961, Cotran, in his study of 9050 cases of BCCs, reported 
metastatic lesions in 0.1% of cases, with the tumour cells in the metastatic 
foci having the histological appearance of metatypical carcinoma. In the 
1960s the best treatment option for BCCs to prevent recurrences, were 
analysed. Knox et al (1960) stated that curettage followed by 
electrodessication is a widely used method. Van Scott and Reinertson (1961) 
demonstrated the stromal dependency of the epithelial components of BCCs. 
In their studies, BCCs only grew when the epithelial component was 
transplanted with the stromal component. The issue of sub-typing with 
respect to recurrence emerged with the study of Hayes in 1962. He 
concluded that the multifocal type of lesion was more prone to recur. 
In the 1970s, the importance of the typing of BCCs in predicting recurrence of 
tumour emerged (Rintala, 1971; Freeman and Duncan, 1973; Jackson and 
Adams, 1973). In addition, this decade expanded the histopathological 
spectrum of BCCs (Borel, 1973). 
In 1977, Sloane examined 156 BCCs in his attempt to address and predict 
tumour recurrence. He divided the tumours into 4 main groups: 
1. nodular 
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2. nodular with an infiltrative margin 
3. infiltrative 
4. multifocal 
The infiltrative and multifocal types had a high rate of recurrence while 
recurrence was rare in the nodular type. In addition, some parameters which 
were not contributory in terms of prognostic value, included the various types 
of epithelial differentiation and stromal factors. Ten-Seldam and Helwig 
(1974) added the morphoea-type of lesion to the group of lesions with a 
greater potential to recur or progress. 
2.1.2 RECURRENT BASAL CELL CARCINOMAS 
Taylor and Barisoni (1973) stated that many factors influenced their diagnosis 
of a recurrent BCC. Often they had great difficulty in deciding whether a 
lesion which reappeared in the same site was a true recurrence or a new 
lesion. They eventually designated lesions as recurrent when suspicion of 
recurrence was queried by the surgeon on the clinical notes or the pathology 
requisition. Thus the referring physician, the patient or the surgeon himself 
noted the presence of some abnormalities in or immediately adjacent to the 
scar of previous removal or repair (Taylor and Barisoni, 1973). Some have 
thought that a recurrent BCC was a different lesion from a primary BCC 
(Sakura and Calamel, 1979). Because it recurred, they thought it had been a 
more aggressive lesion from its onset (Sakura and Calamel, 1979). 
In 1986, Lang and Maize chose to study recurrent basal cell carcinomas to 
determine whether these BCCs become more biologically active with each 
recurrence or whether these BCCs have aggressive histopathologic features 
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in the original lesions. Their study included 47 patients with 51 original 
tumours and all their recurrences. The patients that were included had to 
have at least one suitable slide from their original lesions and from each 
recurrent lesion. The treatment modality for the original tumours were also 
known. Forty patients were treated by electrodessication and curettage and 
10 BCCs had been treated by excision with 4 having margins involved by 
tumour. Examination of the original tumours showed that 65% had a 
prominent micronodular and/or infiltrative element that usually showed poor 
palisading. Lang and Maize (1986) believed that it was important to note the 
infiltrative and micronodular elements, because they appeared to correlate 
with an increased tendency for recurrence. Lang and Maize (1986) concluded 
that most of the recurrent tumours are aggressive from the beginning. They 
also believed that this aggressiveness could often be predicted from 
pathologic examination of original lesions. These aggressive tumours may be 
very destructive if inappropriately or inadequately managed. The findings of 
Lang and Maize (1986) were similar to those of Sloane (1977), Jacobs et al 
(1982), Thackray (1951), Afzelius et al (1980) and Mehregan (1983). These 
authors observed BCCs that showed poor palisading and consisted of 
micronodular and infiltrating strands of tumour, concluding that these tumours 
were more likely to recur, invade deeply and show aggressive biologic 
behaviour (Lang and Maize, 1986). They also believed that blind procedures 
such as curettage and electrodessication, cryosurgery and radiation therapy, 
contraindicated in tumours with aggressive histologic pattern, should also be 
used in carefully selected nodular BCCs. Analysis of recurrent BCC lesions is 
difficult because initial treatment, as well as location, histology and size 
CHAPTER 2 11 
appear to play a role in their development. Primary BCCs are commonly 
located on the head and neck; these areas are exposed to ultraviolet rays 
(Koplin and Zarem, 1980). The malar area and nose account for 41.5% of all 
head and neck BCCs with the nose comprising 25% of all facial lesions. 
Ninety seven percent of all recurrent lesions are located in the head and neck 
region with recurrences on the trunk and extremities being very rare (Dubin 
and Kopf, 1983). The combined nasal, malar and peri-orbital areas comprise 
over 75% of all recurrent BCCs (Koplin and Zarem, 1980). These areas have 
high recurrences. Due to fears of deformity and loss of function when these 
lesions are treated, many patients are also reluctant to undergo further 
treatment for a BCC when symptoms such as bleeding and crusting have 
cleared after the biopsy (Sakura and Calamel, 1979). In 1983, Dubin and 
Kopf included several factors that were correlated with recurrence rates, 
treatment modality, age and gender of patient, anatomic site, largest diameter 
of lesion, and previous treatment to determine which factors were associated 
with recurrence. One thousand four hundred and seventeen BCCs treated 
between 1955 and 1969 were analysed. The majority of lesions (758/1417) 
were treated with curettage-electrodessication, of which 197 (26%) recurred 
within 5 years. None of the lesions <2mm in diameter recurred within the 5 
years. The recurrence rate increased with increasing diameter, such that half 
of all lesions over 30mm recurred. Lesions that received prior therapy (40%) 
and those that did not receive prior therapy (25%) recurred. Recurrent rates 
also increased substantially with the patient age at treatment: Seventeen 
percent for patients under 40 years of age and ranging up to 33% for patients 
over 70 years. Anatomic sites with increased risk of recurrence were eyes, 
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nose, face, ears and forehead, accounting for 94.5% of all recurrences (Taylor 
and Barisoni, 1973; Koplin and Zarem, 1980). Conservative modes of 
treatment in these crucial areas is thought to play a role in recurrence. Non-
head location is generally associated with non-recurrence. Of four hundred 
and twelve lesions treated by X-ray therapy, 9.7% recurred within 5 years. 
When study factors were examined individually, only sex was significantly 
associated with the risk of recurrence. Men (12.9%) had double the 
recurrence rate of women (6.6%). A total of 247 lesions were treated with 
surgical excision, of which 23 (9.3%) recurred. The only significant factor was 
previous therapy. Patients whose lesions had received previous therapy had 
a significant higher recurrence rate of 19.4% than the patients whose lesions 
had not previously been treated (7.6%). Taylor and Barisoni (1973) stated 
that due to an increase in the risk of recurrence, BCCs in the following 
categories probably required observation over a period of 3 years: 
a) lesions in the nasal and periorbital regions 
b) lesions which had already recurred following any form of treatment 
c) lesions in which residual tumour was reported in the margin of 
resection. 
Some authors have clearly shown that the type of treatment modality plays an 
important role in both primary and subsequent recurrence, with Moh's 
microsurgery demonstrating lower recurrence rates and electrodessication 
and curettage having highest recurrence rates (Sakura and Calamel, 1979). 
Some authors assert that the risk of BCC recurrence varies with its 
histopathologic type. Morphoeic and metatypical (basosquamous) subtypes 
CHAPTER 2 13 
and BCCs with a prominent micronodular or infiltrative component are 
associated with recurrence (Lang and Maize, 1986; Siegle etal, 1986; Dixon 
et al, 1991). While some authors state that no one histologic growth pattern 
of BCC is more likely to recur than another, attributes such as spiky shape of 
cell groups, infiltrating invading edge, poorly developed peripheral palisading, 
moderate to marked degree of nuclear pleomorphism and increased mitotic 
figures are associated with recurrence (Dixon et al, 1989). Some authors 
have suggested that tumour size is a clinical factor predisposing to recurrence 
and increased subclinical extensions are seen with larger lesions (Roenigk et 
al, 1986; Dixon et al, 1989; Ko et al, 1992). The distance to the closest 
resection margins has also been regarded as a factor predisposing to 
recurrence. 
2.1.3 SCAR BCCs 
2.1.3.1 EXTRACUTANEOUS MALIGNANCIES AND SCARS 
2.1.3.1.1 THE LATE 19™ CENTURY UP TO THE 1940s 
In 1828, Jean-Nicolas Marjolin was the first to describe a malignant ulcer 
which occurred in areas of chronic scarring (Bostwick et al, 1976). However, 
the true description of this process was made by Robert Smith who named 
the process "Marjolin's ulcer" (Celikoz et al, 1997). Scar carcinomas have 
been known to arise in areas of scarring from various causes which include 
scars induced by burns, trauma, vaccination and chickenpox. The earliest 
observation of malignant degeneration in burn scars is credited to Celsus, in 
the first century (Giblin et al, 1965). In 1833, Hawkins had reported two 
instances of malignant degeneration in burn scars which had developed in the 
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scars of English soldiers who had been burned in India (Giblin etal, 1965). 
Broca (Giblin etal, 1965) observed malignant degeneration and ulceration on 
a 75 year old man who had been burned 51 years previously. Treves and 
Pack (1930) presented an excellent analysis of the development of cancer in 
34 burned patients. Scar formation is a distinct process in malignant tumours. 
Several studies have argued that the scar might follow, rather than precede 
the carcinoma. According to Treves and Pack (1930) scar is less highly 
organized than the original skin and therefore more liable to ulceration and 
degeneration. Treves and Pack (1930) believed that repair and regeneration 
in marginal epithelium, which result from recurring ulceration in poorly 
vascularized scar tissue lead to neoplastic change. Roffo (Clements et al, 
1995) suggested that misplaced epithelial cell group were responsible, while 
Virchow (Clements etal, 1995) believed that chronic irritation played the 
primary role and Treves and Pack (1930) attributed it to the release of toxins. 
Scar cancer of the lung was first described by Freidrich in 1939 as a 
peripheral carcinoma growing around a scar (Madri and Carter, 1984). 
Impressed by the mature acellular appearance of the central scar, Friedrich 
concluded that scarring preceded the development of neoplasia and acted as 
a carcinogenic focus. As a zone of necrosis separated the central scar from 
viable neoplastic tissue in many scar cancers, he argued that neither healing 
by scar nor accumulation of anthracotic pigment could occur in the center of a 
necrotic neoplasm, and considered this observation supportive of his 
interpretation (Kolin and Koutoulakis, 1988). MacKenzie and Rous (1941) 
proposed an elaborate two-stage mechanism. In the "initiating" phase, normal 
cells are changed to dormant cells secondary to exposure to irritants such as 
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sunlight. Subsequently a "promoting" phase induced by a burn encourages 
dormant cellular dedifferentiation into neoplastic cells. Schrek (1941) has 
stated that 18% of all malignant tumours of the scalp, trunk, legs and arms 
develop in pre-existing scars. 
Neuman (Arons etal, 1966) summarized the four possible aetiological 
mechanisms relating to the formation of cancers in scars. They are: 
1) Local environmental changes in both epidermis and dermis. 
2) Action of cancer as a co-carcinogen. 
3) Carcinogenic agents, which may accompany the trauma. 
4) Implantation of living epithelial elements into the dermis. 
Warren (1943) provided a list of minimal criteria that are critical to implicate 
mechanical trauma as the aetiopathogenesis of tumour: 
1) The integrity of the tumour site prior to injury must be established 
2) The injury must be sufficiently severe to disrupt the continuity of the 
tissue at the site, and so initiate reparative proliferation of cells 
3) The tumour must follow the injury by a reasonable length of time 
4) The tumour must be of a type, which might reasonably develop as a 
result of the regeneration and repair of those tissues which had 
received the injury. 
Other workers have emphasized the importance of the alteration in connective 
tissue, probably hyalinization, and the presence of exogenous collagen with 
fibrinoid change, in burn scars (Iregbulem, 1987). These changes are said to 
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precede post burn malignancy, induced by initiating abnormal metabolic 
activity. Mouly (Arons et al, 1966) observed that lesions such as cigarette 
burns of the lower lip produce a special type of "acute" cancer. Bondi (1960) 
reported cases of carcinoma developing in amputation stump scars. Giblin et 
al (1965) estimated that 2% of burn scars undergo malignant change, and the 
changes usually occurred on the extremities and scalp. The behaviour 
pattern of scar tissue carcinoma has often been minimized and the problems 
of prevention, recognition, pathologic diagnosis and surgical therapy have 
often been overlooked (Arons et al, 1966). Castillo et a/(1968) have 
proposed that a depressed immunological state surrounding a burned area 
was involved in the initiation and development of burn scar cancer. Crawley 
et al (1978) stated that scar carcinoma is a notoriously aggressive tumour with 
a high potential for metastases, due to reports suggesting that this is due to 
the origin of the carcinoma from an "immunologically privileged site", or it is 
due to the anaplastic nature of the tumour itself. 
Various observers have reported that scar carcinoma accounts for 
approximately 7-15% of primary lung malignancies (Auerbach et al, 1979; 
Carroll, 1962; Limas et al, 1971). Oscar et al (1979) defined scar carcinoma of 
the lung as a peripherally located tumour having no evidence of bronchial 
origin and occurring in intimate relation to scar tissue. In their review of 1186 
cases of lung cancer over a 21 year period, Oscar et al (1979) found a total of 
7% peripheral cancers that were related to scars. Most authors suggest that 
the scar is the result of a focal fibrosing process such as tuberculosis, 
organized pneumonias and pulmonary infarction, or exposure to certain 
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substances, such as asbestos and silica. They stated that while most of the 
scars were of tuberculous origin, some were caused by infarcts. In addition to 
these reports of tuberculosis or infarcts as the cause of scar, there have been 
few reports in which scar resulting from trauma (foreign body such as bullet, 
knife-blade or grenade splinters, or a ruptured abscess) have been related to 
the carcinoma (Cagle et al, 1985). 
Myofibroblasts, described in wound healing and conditions of scarring, are 
also a notable feature of desmoplasia in carcinoma of the breast (Lipper et al, 
1980; Seemayer et al, 1980). Battersby and Anderson (1985) were the first to 
report the presence of myofibroblasts in radial scars of the breast. Cagle et al 
(1985), in an autopsy study, suggested that the prognosis of pulmonary scar 
cancers tends to be poor due to the peripheral location of these tumours and 
because of a tendency to metastasize, while clinically undetectable. Although 
there is no universally accepted theory for the development of burn scar 
carcinoma, it would appear that chronic inflammation, the presence of 
infection and poor initial wound management are implicated in the 
pathophysiology of this condition (Celikoz et al, 1997). 
2.1.3.2 CUTANEOUS MALIGNANCIES AND SCARS 
Cutaneous scars are considered poorly organized and vascularized areas and 
therefore, are more liable to ulceration, degeneration and eventually 
malignant transformation. Malignant change in smallpox vaccination scars 
has been infrequently described in the world medical literature. According to 
Kulwin (1975), a total of 54 cases have been reported, of which 31 were 
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BCCs arising in small pox vaccination scars, nine were squamous cell 
carcinomas, and a surprising 13 (24%) were malignant melanomas. The 
patient age ranged from 40-60 years, and in most cases vaccinations had 
been performed more than 30 years before the appearance of the lesions. 
Malignant changes in burn scars have long been reported in the literature 
(Nishimoto et al, 1996). These tumours in most cases are squamous cell 
carcinomas, although other types of malignancies, such as malignant 
melanomas and sarcomas, can be seen rarely (Yucel et al, 2000). The 
second most common histological type of malignancy originating from chronic 
wounds is BCCs (Yucel et al, 2000). Squamous cell carcinomas on burn 
scars occur predominantly on the extremities, while most BCCs occurring in 
burn scars are located in the head and neck area, with a few exceptions 
occurring on the extremities and chest (Martin et al, 2005). In 1996, Chowdri 
and Darzi studied 72 post burn carcinomas in the Kashmir valley. Flame 
burns, of which 32 were due to Kangri burns, accounted for 56 cases, scalds 
occurred in 11 patients and electric burns in the remaining 5 patients. All the 
post-burn scar cancers were well-differentiated squamous cell carcinomas. In 
1930, Treves and Pack treated 1091 patients' with squamous skin carcinomas 
and 1374 patients with BCCs. Of these 21/1091 (2%) squamous and 7/1374 
(0.3%) BCCs arose in burn scars. In 1983, Nancarrow assessed 
malignancies arising in scars, labelling them cicatricial cancers'. BCCs were 
excluded from the study, since BCC histories were much longer than the 
history of the scar, making "retrospective substantiation of a pre-existing 
benign lesion less easy" (Nancarrow, 1983). Of 18 cicatricial cancers, 5 arose 
in burn scars, 5 in radiotherapy induced, 4 in varicose ulcers, 3 in post-
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traumatic scars and one in a scar induced by lupus vulgaris. All of 18 
cicatricial cancers were squamous cell carcinomas. The age of onset of 
cicatricial squamous is lower than in spontaneous onset squamous cell 
carcinomas (Nancarrow, 1983). 
2.1.3.3 BCCs AND SCARS 
Carcinomatous changes have been reported as occurring in scars from a 
multiplicity of causes; such cutaneous cancers have been referred to as 
cicatricial or scar cancers (Nancarrow, 1983). Since the turn of the 19th 
century, reports have confirmed that cancer can arise in old burn scars, 
chronic ulcers, sinus tracts, fistulas and long-existing wounds where a 
prolonged process of repair had taken place (Giblin et al, 1965). Previous 
reports have described BCCs developing with heat, involving small areas of 
the skin, such as splattering of hot oil, metal chips, or molten metal. 
Histologically, all have been of the nodulo-ulcerative type (Treves and Pack, 
1930). It was experimentally proven that within the scarred area, tumour cells 
that are normally rejected, are allowed to grow (Freund et al, 1976). The scar 
acts as an immunologically privileged site that delays the recognition of 
tumour antigens, enabling tumour growth to a size where the immune 
mechanism is no longer able to prevent continued tumour progression and 
spread (Futrell and Myers, 1972). It is also hypothesised that scarring can 
cause changes to the connective tissue stroma that may play a role in BCC 
growth (Pollack et al, 1982). BCCs have also been described in scars 
induced by burns, trauma, vaccination and chickenpox (Pollack et al, 1982). 
Carcinomas arising in burn scars have been described in the medical 
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literature for about 150 years. Burn carcinomas are more common in Japan 
(Kairo burns) and in Kashmir (Kangri burns) than in the United States. They 
occur more frequently in male patients although burns are more frequent in 
females (Stone and Monteil, 1970). Margolis (1970) reported the first case of 
a superficial multicentric basal cell epithelioma arising on a thermal burn scar. 
Malignant change in smallpox vaccination scars has been infrequently 
described in the world medical literature. Zelickson (1968) reported a case of 
a basal cell epithelioma developing at a site of a vaccination scar after a one-
year duration, and proposed that the vaccination site did not heal but led 
directly to a basal cell epithelioma. Sunlight has been implicated in the 
pathogenesis of BCCs arising in smallpox vaccination scars (Hendriks, 1980). 
What role the scarring process itself plays in the pathogenesis of these skin 
cancers is not well understood. Connolly (1960) proposed that scar tissue 
may be more sensitive to the effects of sunlight because of its decreased 
vascularity and atrophic adnexal and epidermal structures. Several other 
explanations have been proposed regarding the pathogenesis of BCCs 
developing in burn scars (Martin etal, 2005). Ultraviolet light has been 
implicated as a causative factor because the most common location of the 
scar BCCs is the head and neck, a site exposed to sunlight constantly (Martin 
et al, 2005). A relationship between embryological closure lines and BCCs on 
burn scars has also been suggested, as well as BCCs occurring in lesions 
where the sweat glands and hair follicles do not appear to have been 
destroyed (Martin et al, 2005). Malignant change may also be a function of 
the nature of the scar; scars that are prominently depigmented and thickened 
are more likely to undergo neoplastic change (Nancarrow, 1983). As the 
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scarred areas are less elastic and respond poorly to tension, the stress in 
scarred skin over anatomically mobile areas, such as joints, is another 
hypothesised factor for neoplastic change (Nancarrow, 1983). 
2.1.4 TREATMENT OPTIONS 
Most physicians are confident to diagnose and recommend treatment of 
BCCs yet recurrences of these lesions occur with a certain degree of 
frequency (Shanoff et al, 1967). Small tumours with a benign histologic 
pattern can recur and be destructive if inadequately managed especially if the 
tumour occurs in an area noted for its high recurrence rate, such as the 
perinasal area (Lang and Maize, 1986). The average BCC, however, can be 
effectively controlled without danger to life, but a significant number of cases 
are seen in which the tumour becomes difficult to eradicate with all 
reasonable attempts and eventually becomes fatal, usually because of an 
intracranial extension (Shanoff et al, 1967). In other cases, slow but 
relentless progression of this lesion creates widespread tissue destruction and 
severe functional or cosmetic deformity (Shanoff et al, 1967). Treatment of 
BCCs vary, according to size, type, and site of the lesion as well as the age 
and sex of the patient (Hacker et al, 1993). It is generally agreed that no 
single type of treatment is better than any other method at all times (Knox et 
al, 1960). The goal of therapy is permanent cure of the patient with the best 
cosmetic results (Hacker et al, 1993). Therapeutic options include 
electrodessication and curettage, cryosurgery, excisional surgery, Moh's 
surgery and ionising radiation. Knox et al (1960) stated that curettage 
followed by electrodessication is a widely used method for the treatment of 
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skin cancers, but these methods were criticized by other observers that 
preferred surgical excision or irradiation. Knox et al (1960) decided that in 
order for this method to receive proper respect the basic principles involved in 
its use, indications, contraindications and data presenting a cure rate has to 
be published. Knox et al (1960) studied patients who had a histopathological 
diagnosis of BCC or squamous cell carcinoma, had been treated by curettage 
and electrodessication during the period between 1 January 1939 and 1 
January 1959 and followed for a 5 year period. The method was used 
whenever lesions were well circumscribed and not large or destructive. The 
results of this study, which included 67 patients with 90 lesions, was a 5 year 
cure rate of 96,67% with only 3 recurrences. Knox et al (1960) agreed that 
lesions treated by this method should be <2cm in diameter and should be 
non-destructive (no invasion of deeper structures). 
CURETTAGE AND ELECTRODESSICATION 
In curettage and electrodessication, the sharp cutting blade of the curette is 
used to remove the tumour mass of either inward or outward growing lesions, 
making it a valuable tool in determining the depth and extent of the 
epithelioma (Knox et al, 1960). Clarke in 1910 defined "dessication" as the 
method by which benign or malignant growths may be destroyed by the 
utilization of heat of just sufficient intensity to dehydrate the tissue (Knox et al, 
1960). After curettage, electrodessication is utilized to destroy any abnormal 
cells that may remain at the base or sides of the operative site and also at the 
same time provide hemostasis (Knox et al, 1960). The cells become 
shrunken and shriveled, and nuclei are condensed and elongated (Knox et al, 
CHAPTER 2 23 
1960). This procedure can be performed quickly and requires a minimum of 
office visits, the cosmetic results are usually excellent and the cure rate is 
very high in properly selected areas. The disadvantages are that this method 
is not appropriate for large and invasive lesions, an electrodessicated surface 
will not heal as rapidly as an excision site and healing may be slow over areas 
of poor vascular supply. 
Cryosurgery, that employs liquid nitrogen at a temperature of -195.8 °C, is 
applied to the lesion (Hacker etal, 1993), and followed by 1-3 minutes of 
thawing time. The advantages are that it is easy, fast and cheap to perform 
and does not cause blood loss or require anesthesia. The disadvantages are 
patient discomfort with therapy, delayed healing time and occasionally 
hypopigmentation (Hacker et al, 1993). 
Surgical excision is a very effective method, particularly for large lesions that 
are situated in high risk areas. Often a simple ellipse with suturing is feasible. 
However, in more difficult anatomic sites, the use of skin flaps and grafts may 
be necessary. A minimal margin of 4mm is required for tumours smaller than 
2cm to eradicate the entire cancer (Hacker etal, 1993). 
The cure rate with MOH'S Surgery is 99% for primary BCCs and 96% for 
recurrent lesions. This technique is used for the following tumours: 
• tumours situated in areas where the risk of recurrence is high 
• tumours with poorly defined clinical borders or surface changes 
D recurrent tumours 
CHAPTER 2 24 
• morphoeaform tumours 
• incompletely excised tumours 
• large tumours 
By using Moh's surgery a tumour can be completely excised in a day without 
removing more than 1-2mm of normal skin (Hacker etal, 1993). 
Radiation therapy may be used when surgery is not feasible or surgical 
destruction is not desirable. This method should not be used in the following 
cases: 
• lesions in areas such as in the inner canthus, where recurrences might 
be catastrophic 
• lesions in patients younger than 50 years, who would be subject to 
long-term sequelae such as carcinogenesis and chronic radiation 
dermatitis 
• lesions in previously irradiated areas 
D morphoeaform BCCs (Hacker et al, 1993) 
2.2 BCC VARIANTS 
The criteria for defining a giant BCC included a lesion that was more than 
10cm in size or had an average area of greater than 80cm2 (Randle et al, 
1993; Sahl et al, 1994; McElroy et al, 1996). At present the acceptable 
criteria for a giant BCC is 5cm, although other factors, including age of the 
lesion, the site location, histologic subtype and possible previous therapeutic 
modalities also influence outcome. Granular cell BCCs, described in 1979 by 
Barr and Graham, contain typical neoplastic aggregates composed partially or 
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completely of granular cells. Reichel (1997) described a granular cell BCC in 
which granular cells arose from the base of a typical nodular BCC. 
White et al (1991) reported a case of signet ring BCC, which had the 
presence of keratin within these signet ring cells as opposed to the presence 
of altered lysosomes and glycogen in signet ring clear cell BCC that was 
described by Cohen and Zaim (1988). Although pigmented BCCs were 
described in the 1920s, Maloney et a/(1992) recognised deficiencies in the 
literature, and investigated the frequency, type of pigment and its location, the 
histologic growth pattern and the frequency of margin involvement in 
pigmented BCCs. In their findings pigment was present most commonly in 
the mixed nodular/micronodular subtype. The pigment was confirmed to be 
melanin in all lesions. In 1993, a new variant of BCC, in which monster cells 
were indentified, was described by Elston et al. Unlike the BCCs with giant 
cells, these monster cells were not multinucleate in type and they did not 
contain eosinophilic nuclear granules and spherical basophilic bodies that 
were described by Ochiai et al in 1987. Fibro-epithelioma of Pinkus, which 
was recognised as a distinct entity in 1953, received greater attention in the 
nineties (Pinkus, 1953). In 1994, Stern et al suggested that most, but not all, 
cases of fibroepithelioma of Pinkus, owed their characteristic histologic 
pattern to the growth and extension of BCC cells down eccrine ducts. 
Requena et al (1996) described a new clinicopathological variant of BCC that 
they designated keloidal basal cell carcinoma. In their two cases, keloidal 
tissue was present in the stroma of primary BCCs. In 1997, a variant of BCC 
with thickened basement membrane was described (El-Shabrawi and LeBoit, 
1997). The basement membranes stained positively with periodic-acid Schiff 
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and with antibodies to type IV collagen and laminin. While type IV collagen 
stained the entire basement membrane and the hyaline globules within the 
tumour, laminin showed continuous staining only at the inner edge of the 
membrane. According to the authors, the existing theory that thickened 
basement membrane around epithelial cell nests signified a benign cutaneous 
epithelial neoplasm, was flawed by the new BCC variant. 
2.3 THE EXTRACELLULAR MATRIX 
The extracellular matrix is a dense lattice work of collagen and elastin 
embedded in a viscoelastic ground substance composed of a mixture of 
collagenous and non-collagenous proteoglycans and glycoproteins (D' 
Ardenne, 1989). The composition and arrangement of basement membranes 
differ in different sites according to functional requirements (Damjanov, 1990). 
Basement membranes are a supporting scaffold which isolates tissue 
compartments, mediates cell attachment and influences tissue architecture. 
The matrix also acts as a selective macromolecular filter and plays a role in 
mitogenesis and differentiation. Interactions between the normal cells and the 
matrix may be altered in neoplasia and this may influence tumour proliferation 
and invasion. The vertebrate organism is separated into tissue compartments 
bordered by the basement membrane and interstitial stroma (Liotta, 1986). 
2.3.1 GENERAL FEATURES OF THE BASEMENT MEMBRANE 
Basement membranes are ubiquitous, thin, sheet-like structures located 
beneath epithelia and endothelia: They surround muscle, nerve and other 
tissues of mesenchymal origin (Zhou et al, 1994). Basement membranes are 
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extracellular matrices that are found in various regions of the skin (Weber et 
al, 1982). These membranes are complex structures composed of a mixture 
of collagenous glycoproteins, non-collagenous glycoproteins and 
proteoglycans (D'Ardenne, 1989). The collagenous glycoproteins is a 
meshwork of type IV collagen which is the structural backbone of the 
basement membrane (Liotta, 1986) and the high molecular weight non-
collagenous protein is known as laminin (Timpl et al, 1979). Although the 
basement membrane is actively involved in preserving the integrity of organs, 
it also contributes to their specialised functions (Vracko, 1974; Gorstein, 
1988). Fibronectin is another large glycoprotein that is present in plasma, on 
the cell surface, and in many basement membranes. Fibronectin mediates 
the attachment of a variety of cell types, whereas type IV collagen and laminin 
may be involved in the attachment of epithelial cells. Basement membranes 
separate the parenchymal cells from their underlying connective tissue 
stroma, forming a barrier to the passage of macromolecules from blood 
(Foidart, 1980). They also form the normal substrate for endothelial and 
epithelial cells and are involved in the morphologic differentiation of tissues 
(Foidart, 1980). Interactions between cells and basement membranes occur 
via specific cell surface receptors for different basement membrane 
constituents, and influence cell morphology and differentiation and promote 
cellular adhesion and movement. Several studies have indicated the 
importance of basement membranes in tissue regeneration and repair for 
example, an intact membrane is necessary for regeneration of renal tubular 
epithelium following acute tubular necrosis and for repair of the epidermis 
after skin damage (D'Ardenne, 1989). Basement membranes also act as a 
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filtration barrier and are important in morphogenesis, tissue differentiation and 
regeneration (Vracko, 1974). They play a critical role in tumour invasion 
(Albrechtsen et al, 1981). 
2.3.2 ULTRASTRUCTURE OF BASEMENT MEMBRANE 
Basement membranes are characterised by the presence of a basal lamina. 
This is further subdivided into the lamina densa, which is sometimes referred 
to as the basement membrane proper, and the lamina lucida. The lamina 
densa consists of tightly matted, randomly orientated fibrils, 3-4nm in 
diameter, which is embedded in a dense matrix. The basement membrane is 
composed of several proteins such as type IV collagen, laminin, proteoglycan, 
and entactin (Hudson et al, 1993). 
2.3.3 BASEMENT MEMBRANE IN TUMOURS 
Basement membranes are affected in a number of genetic and acquired 
diseases (Zhou et al, 1994). One of the first barriers to carcinoma invasion 
into surrounding tissues is transgression of basement membranes (Zhou et al, 
1994). Benign epithelial neoplasms are always surrounded by an intact 
basement membrane even though they may "expand" into adjacent host 
tissues (Barsky etal, 1983). These basement membranes are structurally 
and biochemically indistinguishable from those in normal adult tissues 
(Willebrand et al, 1986). Malignant tumours on the other hand lose their 
extracellular basement membrane, during the process of tumour invasion. 
Immunohistochemical techniques using antibodies against different basement 
membrane constituents have been undertaken to: 
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• confirm tumour invasion 
• distinguish malignant from benign "look-alikes" 
• determine tumour prognosis 
• determine tumour histogenesis (D'Ardenne, 1989). 
2.3.4 BASEMENT MEMBRANE: FUNCTION 
The basement membrane plays a role in cell adhesion and differentiation, as 
well as in tissue regeneration. They also have an important function in the 
size-selective sieving of macromolecules in renal glomeruli. 
2.3.5 NORMAL BASEMENT MEMBRANE OF SKIN 
The basement membrane of the epidermis is an interface between the dermis 
and epidermis. It supports the basal cells, moors the epidermis to the dermis 
and is a zonal barrier to cells and molecules that are localised to one or other 
compartment (Stenn and Bhawan, 1990). On light microscopy, the basement 
membrane is highlighted with glycoprotein stains, as a thin, well defined 
sheath beneath the epidermis. 
2.4 IMMUNOHISTOCHEMISTRY 
The rate at which a tumour proliferates has long been considered to bear a 
relationship to its clinical course. Histopathologists have therefore sought 
means of determining this as an adjunct to diagnosis. A variety of methods 
have been adapted, including mitotic counts, use of tritiated thymidine or 
bromodeoxyuridine incorporation and flow cytometry. Some of the above 
methods are not reliable in terms of accuracy, eg. the mitotic count of a BCC 
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may be high, but this is due to the prolonged M-phase of the cell cycle rather 
than a high proliferation rate in the tumour itself. Some of these methods are 
difficult, expensive and time consuming and are not within the domain of the 
general surgical pathologist. By contrast, immunohistochemistry is simple, 
familiar to most pathologists and is in general, diagnostic. In distinguishing 
benign from malignant tumours, a positive result is supported by the negative 
observation (lack of basal lamina immunoreactivity). It is critical, therefore, to 
ensure that the immunohistochemical stains have actually "worked" 
(D'Ardenne, 1989). 
2.4.1 LAMININ 
Laminin is a high molecular weight non-collagenous glycoprotein (Foidart, 
1980). It consists of three chains: a, 6 and y chains connected by an alpha-
helical coiled domain that is synthesized by epithelial cells, endothelial cells or 
differentiated myotubes. Laminin was originally thought to be a third chain of 
type IV collagen, but resistance to collagenase indicated its non-collagenous 
nature. Ultrastructurally, laminin is localized in the lamina lucida of the human 
epidermal basement membrane. The laminin molecule has a cross-like 
structure with one long arm and three short arms (Kallunki, 1992). Laminin 
consists of one heavy a chain of 400KD and two light chains 61 and 62 of 
200KD each. The a chains have three globular domains at their amino 
terminus which are separated by EGF-like repeats, a coiled-coil domain and a 
large globular domain at the carboxy terminus containing five globules 
(Malinda and Kleinman, 1996). The 6 and y chains are shorter than the a 
chains. They contain two globular domains and two EGF repeats at the 
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amino terminus only. The long arm is formed by heptad repeats typical of a-
helical coiled-coil proteins and the short arms are formed of EGF-like modules 
and domains. 
2.4.1.1 FUNCTIONS 
The functions of laminin include stimulation of cell growth and differentiation, 
and promotion of neurite outgrowth, cell adhesion and locomotion. Purified 
antibody against laminin was used to localize basement membranes by 
indirect immunofluorescence in various anatomical regions of normal and 
diseased human skin. Albrechtsen etal (1981) discovered from their studies 
that the presence of cytoplasmic staining for laminin in ductal epithelial cells in 
areas with normal breast morphology suggested that laminin is continuously 
synthesized by the normal epithelium. Albrechtsen et al (1981) stated that the 
biological significance of this production was not clear, but hypothesized that 
the synthesis was probably necessary to replenish laminin that had been 
broken down. Since malignant cells stained even more strongly for laminin 
than normal epithelial cells, it seems reasonable to conclude that carcinoma 
cells are able to synthesize laminin in vivo. The significance of this synthesis 
is not known, but recent results on the cell-adhesion promoting properties of 
laminin suggest that laminin could be important for the attachment and growth 
of such tumours. 
2.4.1.2 LAMININ EXPRESSION IN BCCs 
Laminin expression in BCCs is either continuous and distinct or discontinuous 
and indistinct basement membrane around tumour aggregates. Generally, 
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aggressive BCCs, including the morphoeic, infiltrative and basosquamous 
types tend to have discontinuous and indistinct basement membranes around 
the tumour aggregates (Barsky, 1983; De Rosa etal, 1994), while the 
converse is true of the non-aggressive BCCs (Markey etal, 1991). The 
presentation of single laminin chains on tumour cell surfaces, and the loss of 
structural basement membrane organisation, may lead to retention of cellular 
adhesion and support tumour cell invasion. A structurally altered basement 
membrane, in addition, is able to modulate the adhesive and invasive 
properties of tumour cells, possibly by virtue of its altered laminin isoforms 
(Albrechtsen etal, 1981). The laminin receptors of normal epithelium may be 
polarised at the basal surface and occupied with laminin in the basement 
membrane (Liotta etal, 1983). In contrast, laminin receptors on invading 
carcinoma cells may be distributed over the entire surface of the cell. They 
may be unoccupied because of the loss of formed basement membrane 
associated with the invading cells. 
2.4.2 FIBRONECTIN 
Fibronectin is a high molecular weight glycoprotein that is found in a soluble 
form in blood and extracellular tissue fluids, and in an insoluble form in 
connective tissues (Erickson et al, 1981). Fibronectin is also present widely 
on the cell surface of fibroblasts, monocytes, endothelial cells and several 
other types of cells (Nagata et al, 1985). Fibronectin is derived from the Latin 
language, "fibra" meaning "fibre" and "nectere" meaning to bind or tie. 
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2.4.2.1 STRUCTURE 
Plasma fibronectin and the cell surface or extracellular matrix forms are 
dimers, comprising two subunits of 220,000 molecular weight, covalently 
linked by a single disulphide bond near their carboxyl termini. Cell surface 
fibronectin differs from plasma fibronectin in carbohydrate content and 
solubility and exists as oligomers of the basic dimeric molecule, but the two 
forms are very similar in amino acid and carbohydrate composition and are 
also immunologically indistinguishable. Plasma and cell surface fibronectins 
are elongated, rather than globular proteins. 
2.4.2.2 FUNCTIONS 
Fibronectin promotes interaction between cells and the extracellular matrix, 
and is present at the dermal-epidermal junction (DEJ) and throughout the 
dermis, but absent in the normal epidermis (Nelson etal, 1983). Fibronectin 
plays an important role in many biologic activities which include: 
- cell-cell adhesion 
- cell-substrate adhesion 
- migration and differentiation of cells 
- maintenance of cellular structure 
- wound healing 
- blood coagulation and opsonic function. 
It is also well known that fibronectin has a special affinity for collagen, heparin, 
fibrin, fibrinogen and hyaluronic acid. 
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2.4.2.3 EXPRESSION IN NORMAL TISSUE 
Fyrand (1979) had undertaken a study on fibronectin in normal skin. The 
group of individuals that made up the study consisted of women with a mean 
age of 40 years and men with a mean age of 41 years. Using indirect 
immunofluorescence Fyrand (1979) discovered that fibronectin was seen 
mainly in the basement membrane, in the papillary dermis and epidermal 
appendages (pilosebaceous units and eccrine sweat glands). According to 
Fyrand (1979) the reticular dermis showed the presence of fibronectin to a 
lesser degree with a different type of distribution. In areas of the skin with 
more ground substance, such as the papillary dermis, the 
immunofluorescence pattern of fibronectin shows a reticular character, 
whereas in the reticular dermis larger bundles of fibronectin give a fibrillar 
pattern. These reticular and fibrillar patterns may be based upon the binding 
of fibronectin to collagen fibres. Nagata et al (1985) demonstrated from their 
studies of normal skin, that fibronectin was found along the dermo-epidermal 
junction, reticulately in the papillary dermis, intercalated between arrector pili 
muscle cells, in the vascular walls of the papillary dermis, and along eccrine 
sweat glands and hair follicles. The epidermis and deep reticular dermis did 
not show any specific immunofluorescence. 
2.4.2.4 FIBRONECTIN IN DISEASE STATES 
Fibronectin plays an important role during tissue re-modelling in 
atherosclerosis, pulmonary fibrosis and glomerulosclerosis (Kosmehl et al, 
1996). Terranova et al (1984) showed that cultured cancer cells from which 
fibronectin was excluded exhibited reduced invasive and metastatic abilities. 
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In 1985, Matsuura and Hakomori documented the existence of two types of 
fibronectin, which were subsequently named "normal fibronectin" and 
"oncofoetal fibronectin". The latter is expressed in various tumours and foetal 
tissues. Fibronectin has diagnostic histopathologic relevance in 
embryogenetic, inflammatory and neoplastic conditions (Kosmehl etal, 1996). 
2.4.3 Ki-67 
Immunohistochemical detection of Ki-67 was originally limited to frozen 
material. However, with the development of monoclonal antibody MIB1, this 
has become possible on archival paraffin embedded tissue although a prior 
antigen retrieval step using microwave incubation is required (Brown and 
Gatter, 1990). 
2.4.3.1 MIB1 ANTIBODY 
MIB1 is a monoclonal antibody which can be used to assess the growth 
fraction, ie. the number of cells in the cell cycle, of normal, reactive and 
neoplastic tissues. MIB1 is an IgG class murine monoclonal antibody (Brown 
and Gatter, 1990), which was generated when mice were immunized with 
nuclear extract from the L428 cell line in the course of raising monoclonal 
antibodies to nuclear antigens specific for Hodgkin and Reed Sternberg cells. 
The antigen was named Ki-67 after its place of production in Kiel, West 
Germany and because the clone producing the antibody was grown in the 67th 
well of the tissue culture plate. 
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2.4.3.2 Ki-67 ANTIGEN 
Antibody MIB1 recognizes an antigen which is associated with the cell 
nucleus. Ki-67 antigen is present in the nucleus of proliferating cells. Gerdes 
et al (1991) have shown that Ki-67 antigen is exposed in all stages of the cell 
cycle, except Go. Some authors found that the amount of Ki-67 antigen varies 
with the phases of the cell cycle. Sasaki et al (1987) found that the Ki-67 
antigen expression increases with cell cycle progression, rising during the 
latter half of the S-phase, and peaking in the G2 and M-phase. Guillard et al 
(1989) also demonstrated an increase in Ki-67 expression through the cell 
cycle in normal and malignant cell lines. Verheijen et a/(1989) used flow 
cytometry and showed the highest staining intensities in mitotic cells with 
similar results described by others. However, some workers reported uniform 
expression of Ki-67 antigen throughout the cell cycle using different cell lines. 
Verheijen et al (1989) revealed that there is a decrease or lack of antigenic 
expression of Ki-67 in all phases of the cell cycle in nutritionally deprived or 
slow growing cells. Brown and Gatter (1990) suggested that tissue from the 
central area of a large tumour might give an erroneously low value for the 
growth fraction. 
2.4.3.3 ANTIGEN DISTRIBUTION 
Investigation of the spatial and temporal patterns of expression of the antigen 
in a variety of normal and neoplastic human cell lines, including morphological 
analyses of the distribution of Ki-67 antigen expression during the cell cycle, 
has revealed that: 
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• the topographical distribution of the antigen appears to be cell cycle 
dependent. 
• in the late Gi phase, the Ki-67 antigen is present in the 
perinucleolar region. 
• there is homogenous distribution of Ki-67 in the karyoplasm in the 
S-phase. 
• in G2, the perinucleolar staining within the karyoplasm is finely 
speckled or granular. 
• during prophase, perichromosomal and karyoplasmic staining is 
present. 
• during metaphase, perichromosomal and cytoplasmic staining is 
seen. 
• with progression from S into G2, the Ki-67 antigen is tightly 
associated with chromatin. 
• during mitosis, all Ki-67 immunoreactivity is co-localised with 
chromatids. 
2.4.3.4 FUNCTIONS: Ki-67 ANTIGEN 
The exact function of the Ki-67 antigen is not known. However, Braun et al 
(1988) suggested that because of its increasing level and continuous spread 
throughout the cell cycle, it acts as a timer molecule. Falini et al (1989) have 
shown that the antigen is present in both neoplastic and normal tissues, 
thereby indicating that this antigen plays an important role in regulation of cell 
proliferation. 
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2.4.3.5 EXPRESSION IN SKIN 
MIB1 immunoreactivity is present throughout the epidermis of the skin. In a 
study by Smith et al (1995), MIB1 positivity was detected in the basal layer 
and suprabasal layer keratinocytes. Although positivity was confined to the 
nucleus, it was heterogeneous in strength. Mitotic figures were strongly 
positive. MIB1 positivity was also noted in cells of hair follicles and 
sebaceous glands. Dermal fibroblasts, sweat glands and endothelial cells 
were non-reactive. 
2.4.3.6 EXPRESSION IN BCCs 
In 1993, Baum etal investigated MIB1 expression and the growth patterns of 
BCCs. In the nodular group of BCCs, 7-67% of cells were MIB1 
immunoreactive, while 18-49% were MIB1 immunopositive in the superficial 
type and 4-33% were positive in the fibrosing group. The staining pattern in 
the tumours varied. In some tumours MIB1 positive nuclei were confined to 
the peripheral 3 to 5 rows, or, were scattered in the central and peripheral 
parts of the tumour. In 1995, Healy et al investigated the MIB1 proliferation 
characteristics of BCCs that recurred and compared results with non recurrent 
BCCs using MIB1 antibodies on 4^m paraffin embedded sections as 
described by Catorretti et al (1992). They found that MIB1 expression was 
significantly higher in primary BCCs which later recurred after complete 
surgical excision, as compared to non-recurrent primary BCCs. Although the 
recurrent BCCs also showed increased MIB1 expression in comparison with 
primary non-recurrent tumours, the increase was not statistically significant. 
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2.4.4 bcl-2 
The 14; 18 translocation was first described in association with follicular 
lymphoma in 1979. In this chromosomal abnormality the gene coding for the 
immunoglobulin heavy chain on chromosome 14 is brought into apposition 
with a previously undescribed gene on chromosome 18. This gene is now 
known as bcl-2 since it was believed to be the second member of a potential 
family of genes involved in the deregulation of lymphoid cells when a 
particular chromosomal translocation has occurred (Pezzella and Gatter, 
1995). The translocation results in the production of abnormally high levels of 
otherwise normal bcl-2 protein and its immunohistochemical detection was 
reported to be a specific marker for tumours with the 14:18 translocation. 
2.4.4.1 FUNCTION 
The physiological function of bcl-2 is different from other oncogenes in that its 
expression does not induce proliferation or transformation but allows cells to 
survive, even without essential growth factors, due to its ability to suppress 
cell death by apoptosis (programmed cell death) in which the cell and its 
nucleus condenses and fragments. This is believed to be the most important 
mechanism of cell death in humans. Vaux et al (1988) were the first to report 
that jbc/-2 can prolong cell survival. 
2.4.4.2 STRUCTURE 
The 25-26kD bcl-2 protein from humans, mice, rats and chickens is a stretch 
of 19 hydrophobic amino acids near the COOH terminus with 2 charged 
residues that presumably serve to anchor the protein in membranes (Cazals-
Hatem etal, 1992; Sato and Kennard, 1993). Mutagenesis studies have 
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confirmed that the hydrophobic COOH - terminal region allows post-
transitional insertion into membranes such that the majority of the bcl-2 
protein should be orientated towards the cystol (Chen-Levy era/, 1989), 
demonstrating the importance of membrane insertion for bcl-2 function as a 
blocker of apoptosis (Hockenberry et al, 1990). A second shorter form of the 
bcl-2 protein that lacks a hydrophobic tail can potentially be produced through 
alternative splicing (Tsujimoto and Croce, 1986), but this protein (termed bcl-2 
beta) has never been seen in vivo in appreciable amounts. 
2.4.4.3 bcl-2 FAMILY OF GENES 
cDNA has been cloned for several human genes. One of these, termed bcl-X, 
encodes a 241-amino acid protein with 74% homology to bcl-2. An additional 
bcl-2 homologue, called bax, was discovered through analysis of jbc/-2 
associated proteins. A 21-kD (192 amino acids) isoform of bax contains a 
transmembrane domain and has 21% homology (43% similarity) with bcl-2. 
Additional members of the bcl-2 family are called Mcl-1 and A1-gene. Mcl-1 
encodes a 37-kD protein that contains a stretch of 139 amino-acids with 35% 
homology (59% similarity). A1 encodes a 20kD protein that has 40% 
homology (Reed, 1994). 
2.4.4.4 EXPRESSION OF bcl-2 IN NORMAL TISSUES 
In adult epithelial tissues bcl-2 expression is related to endocrine activity. 
Proliferative endometrial glands, which are under endocrine control show 
increased bcl-2 expression allowing the cells of the endometrium to survive as 
the menstrual cycle progresses. In the thyroid gland, epithelial cells lining the 
follicles show cytoplasmic staining of bcl-2. Epithelia under hormonal control 
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exhibit variable expression and localisation of bcl-2 protein, bcl-2 expression 
has also been demonstrated in cells that are under endocrine control, such as 
stem cells or proliferating cells including basal cells of the skin (Yang and 
Korsmeyer, 1996; Verhaegh ef al, 1995). It is also expressed in duct cells in 
endocrine glands as well as in salivary and sweat glands. 
2.4.4.5 bcl-2 EXPRESSION IN MALIGNANCIES OF THE SKIN 
BCCs tend to be more bcl-2 positive than squamous cell carcinomas. 
Morales-Ducret et a/(1995) demonstrated 100% positivity in BCCs in contrast 
to 10% in squamous cell carcinomas. Nakagawa ef al (1994) demonstrated 
bcl-2 positive staining in 100% of squamous cell carcinomas in contrast to 
67% of BCCs. Crowson et al (1996) compared bcl-2 expression in aggressive 
and non-aggressive BCCs and found that non-aggressive BCCs exhibited 
greater bcl-2 expression than their aggressive counterparts. 
2.4.5 p53 GENE 
The p53 tumour suppressor gene has acquired great importance in the 
understanding of the origins of neoplasia in human beings (Levine et al, 
1994). 
2.4.5.1 WHAT ARE TUMOUR SUPPRESSOR GENES? 
Tumour suppressor genes encode specific proteins that function to prevent 
cancer development by blocking the division of cells that have sustained DNA 
damage, and in some cases triggering cell death by apoptosis (Lane, 1994). 
Tumour suppressor genes have been divided into two distinct groups based 
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on their functions. This is useful when considering how they prevent cancer. 
The first group, called the "Gatekeeper" genes, are genes that have a direct 
effect on tumour growth by either inhibiting proliferation or promoting cell 
death. These are the classical tumour suppressor genes. The second group 
called the "Caretaker" genes, are genes that influence growth indirectly by 
encouraging cells to produce "genetic mistakes" which increase the likelihood 
that other genes, including "Gatekeeper genes", are knocked out. Functional 
studies have shown that p53 plays a major role in the arrest of cell growth and 
induction of apoptosis following DNA damage. Abnormalities of p53 are one 
of the most frequent abnormalities identified in human skin cancers to date 
(Swale and Quinn, 2000). 
p53 protein was first identified through its ability to form a tight, stable 
complex with the SV40 large T antigen (Lane and Crawford, 1979). The large 
T antigen is a multifunctional protein that has the ability to transform a wide 
range of vertebrate cells and also acts to initiate viral replication (Rigby and 
Lane, 1983; Fried and Prives, 1986). Large T antigen can block the action of 
p53 as a DNA-binding protein and as a transcription factor (Mietz etal, 1992). 
It can also act to block the growth arrest and apoptotic functions of p53 
thereby permitting viral replication/tumour spread. One of the striking early 
findings in the field was of the radical changes in p53 protein levels that were 
associated with transformation (DeLeo et al, 1979). Normal cells contain two 
copies of each tumour suppressor gene and cancer development normally 
requires that both copies of the genes be inactivated. There are several 
different ways in which tumour suppressor genes can be inactivated. In 
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numerous cancers, tumour suppressor genes are inactivated by a 
combination of gene deletion due to chromosome loss and point mutations 
(Swale and Quinn, 2000). 
2.4.5.2 p53 STRUCTURE 
The human p53 gene is located on the short arm of chromosome 17 in the 
17p13 position. Translation to a nuclear phosphoprotein occurs and consists 
of 393 amino acids contained in 11 exons (Levine et al, 1994). The first exon 
is non-coding. When the p53 protein is produced, it turns on the gene for a 
21 kD protein that blocks cdk enzymes and thus cell division (Marx, 1993). 
2.4.5.3 EXPRESSION IN NORMAL SKIN 
The levels of p53 in normal cells and tissues are always low, yet in 
transformed cells, the levels are much higher (Lane, 1994). In normal skin, 
the levels of wild-type p53, a potent suppressor gene, increase following 
exposure to ultraviolet (UV) radiation. This is thought to be an important 
protective response as demonstrated by studies in mice which lack p53, so 
called knockout mice, that show a marked increase in the rate of skin cancer 
development following exposure to UV irradiation. The loss of wild type p53 
expression in most solid tumours is usually the result of a large chromosomal 
deletion (Batsakis and El-Naggar, 1995). Wild type p53 protein blocks 
tumourigenicity of cancer cells in nude mice and suppresses transformation of 
cells in culture (Donehower and Bradley, 1993). p53 mutations have been 
identified in small clones of keratinocytes in sun-exposed human skin which 
suggests that inactivation of this protein is an early event in skin cancer 
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development. 
2.4.5.4 MUTANT p53 
Mutant p53 genes produce proteins that do not bind to DNA and do not 
promote transcription of a usually responsive promoter enhancer and gene. 
Mutant p53 may act in a dominant negative manner (like an oncogene) by 
entering into oligomeric complexes with wild-type p53 and blocking its function 
thereby enhancing oncogenic potential (Deppert, 1994). 
2.4.5.5 p53 AND THE CELL CYCLE 
p53 regulates the initiation of the S-phase and helps to ensure the replication 
of intact DNA alone (Hartwell, 1992; Weinert and Lyndall, 1993; Rotter etal, 
1994). The GrS and the G2-M transition phases are regulated in response to 
DNA damage, thus allowing for DNA repair before entry into the S or M 
phase. Wild-type p53 influences cell growth or division negatively. It is able 
to prevent uncontrolled cellular proliferation by binding to specific DNA 
sequences and inhibiting adjacent gene transcription. Excessive wild-type 
p53 in the late Gi phase of the cycle blocks progression into the S-phase. 
Loss of wild-type activity results in a loss of control at the GrS cell cycle 
check point following DNA damage (Sturzbecher and Deppert, 1994). The 
end result is the production of genetically damaged cells that are vulnerable to 
further damage and capable of yielding neoplastic clones. 
2.4.5.6 p53 EXPRESSION IN MALIGNANCIES OF THE SKIN 
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McGregor et al (1992) used CM-1 anti-p53 antibody to identify p53 protein 
expression in solar keratoses, Bowen's disease, keratoacanthomas, 
squamous cell carcinomas, BCCs, viral warts and normal skin. p53 
immunoreactivity was not seen in normal skin or in viral warts but strong 
nuclear staining was seen throughout the thickness of 50% of squamous cell 
carcinomas, 46% of BCCs, 80% of Bowen's disease and 55% of solar 
keratoses. In 64% of keratoacanthomas, p53 immunopositivity was seen 
mainly in basal keratinocytes. In squamous cell carcinomas, although there 
was no significant difference in p53 immunopositivity in the well, moderately 
and poorly differentiated tumours, strong immunostaining was observed more 
frequently in poorly differentiated tumours. 
2.4.6 THE STROMAL CELLULAR RESPONSE 
2.4.6.1 THE MYOFIBROBLAST 
The discovery of the myofibroblast occurred in electron micrographs from 
contracting (healing) experimental granulation tissue (Gabbiani et al, 1971). 
The myofibroblast is defined by the essential morphologic elements, including 
the presence of bundles of actin filaments with interspersed dense bodies 
running parallel to the long axis of the cell, called stress fibres, as well as the 
presence of well developed cell-to-stroma attachment sites (fibronexus) and 
intercellular intermediate and gap junctions (Schiirch etal, 1998). 
Although the myofibroblast is best defined when visualised with an electron 
microscope, the myofibroblast has several histological features that allow their 
recognition in routine paraffin sections. The myofibroblast has features in 
common with smooth muscle cells and fibroblasts (Seemayer etal, 1980). 
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Histologically, myofibroblasts are usually large, spindle shaped, often stellate 
(spider-like) with long cytoplasmic extensions, and possess distinct acidophilic 
and fibrillar cytoplasm. The nuclei are indented or show strangulations of 
nuclear segments, a feature reflecting cellular contractions. Myofibroblasts 
contain finely granular chromatin and nucleoli are conspicuous. 
Immunohistochemical staining reveals heterogenous cytoskeletal phenotypes 
with regard to their content of intermediate filaments, smooth muscle actin, 
and myosin expression. The myofibroblastic phenotype is determined by the 
expression of vimentin, actin, myosin and desmin (Schurch etal, 1997). 
The various cytoskeletal phenotypes disclosed by the myofibroblasts are as 
follows: 
• Phenotype V is represented by cells that only express vimentin 
• Phenotype VAD is represented by cells that express vimentin, a-
smooth muscle actin and desmin 
• Phenotype VA is represented by cells that express vimentin and a-
smooth muscle actin 
• Phenotype VD is represented by cells that are positive for vimentin and 
desmin. 
Myofibroblasts have been described in normal tissue of human and animals. 
Stromal cells with myoid features were identified in rat and human lymph 
nodes, as well as in human spleen and expressed desmin, a-smooth muscle 
actin, smooth muscle myosin, and vimentin (Toccanier-Pelte etal, 1987). 
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Myofibroblasts have been described during analyses of many pathological 
conditions, during which three processes emerge: 
1) Responses to injury and repair phenomena: Myofibroblasts have been 
demonstrated in granulation tissue where they are well developed and 
numerous in the exudatoproductive layer (Ryan etal, 1974). 
2) The quasineoplastic proliferative conditions: Include fibromatoses of 
soft tissue and bone and other soft tissue proliferations that mimic 
sarcomas (Schurch etal, 1998). 
3) The stromal response to neoplasia: Many invasive and metastatic 
carcinomas are characterized by a desmoplastic stromal reaction that 
is rich in myofibroblasts. Although it was believed that the 
myofibroblastic response represented a host response to the presence 
of cancer in an attempt to limit the spread of tumour, it has been 
hypothesized that the myofibroblastic response promotes cancer 
invasion by secreting stromal degrading enzymes (Seemayer et al, 
1980). 
2.4.6.1.1 ACTIN 
Actin is a ubiquitous cytoskeletal protein that is composed of microfilaments 
(Tsukada etal, 1987a; Enzinger and Weiss, 1995). Actin is present in large 
amounts in muscle as a thin 5-7^m diameter filament composed of globular 
subunits organised in a double stranded helix (Junqueira et al, 1992). It is 
also present in non-muscle cells. Structural and biochemical analyses have 
shown that actin may be an important component of the total protein of all 
cells. In skeletal muscle, actin assumes a paracrystalline array that is 
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integrated with thick (16um) myosin filaments. In most cells, actin filaments 
are present as a thin sheath just beneath the plasmalemma. They may be 
intimately associated with cytoplasmic organelles, vesicles and granules or 
they may form a "purse-string" ring of microfilaments, whose constriction 
results in cleavage of mitotic cells. Different cell types contain 
immunochemically distinct actins that vary in amino acid sequence, and 
isoelectric point (Junqueira etal, 1992). 
With regards to actin expression, there are six isoforms found in mammals 
which share more than 90% homology throughout the entire molecule, but 
each has a unique sequence in the first 18 residues (Collins and Elzinger, 
1975; Vandekerckhore and Weber, 1978). The six actin isoforms are: 
1) two non-muscle actins which are B and y isoforms; these are called the 
cytoplasmic actins 
2) two smooth muscle actins which are the a and y isoforms 
3) two sarcomeric actins which are the a-cardiac and a-skeletal isoforms. 
Skeletal, cardiac and vascular smooth muscle each contain unique a-actins. 
Actins of B and y-motility are found to be in non-muscle cells. Chicken gizzard 
smooth muscle contains a y-actin that differs from the non-muscle isozyme. 
The presence of distinct actin isotypes in muscle cells suggests that some 
actin variants are specifically tailored for cell contraction (Rungger-Brandle 
and Giabbiani, 1983). The expression of actin isoforms in smooth muscle 
cells is modulated during physiological, pathological and in vitro conditions, 
but is always characterised by the presence of a-and-y-smooth muscle and of 
B-and-y-cytoplasmic actins in variable amounts (Tsukada etal, 1987b). The 
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distinction between a-smooth muscle actin and the sarcomeric actins is an 
important means by which to evaluate the smooth muscle or striated muscle 
derivation of neoplasms of mesenchymal origin (Tsukada et al, 1987b; 
Enzinger and Weiss, 1995). Actin has been hypothesised to play an 
important role in the modifications of cell motility during in vivo regenerative 
and tumoural conditions. 
Monoclonal and polyclonal antibodies to actin isotypes have been described. 
A monoclonal antibody specific to smooth and skeletal muscle has been 
reported by Lessard et a/(1983), while Lubit and Schwartz (1980) generated 
a polyclonal anti-actin antibody that was reactive with non-muscle ((3) actin 
isotypes. Gown et al (1985) described a smooth muscle-cell-specific 
monoclonal antibody, CGA7, which reacted with smooth muscle alpha and 
gamma actin isotypes only. Tsukada et al (1987) reported the generation of 
HHF35, an actin antibody, which detected an epitope common to the actin 
isotypes of all muscle cell types, but not the actin isotypes of non-muscle 
cells. In pathologic tissues, HHF35 was present in myofibroblasts, intimal 
cells in atherosclerotic plaques, reactive mesothelial cells and sarcomas of 
muscle origin (Gown etal, 1985; Tsukada etal, 1987b). 
2.4.6.1.2 DESMIN 
Desmin is an intermediate filament which has a molecular weight of 53 000 
kDa and can be found to be present in smooth and striated muscle (Enzinger 
and Weiss, 1995). With synemin and filamin, desmin forms the peripheral 
domain of Z-bands in adult striated muscle (Tokuyasu etal, 1983), as well as 
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an interconnecting network that ensures proper myofibril alignment during the 
contraction relaxation cycle. Desmin is associated with cytoplasmic dense 
bodies and subplasmalemmal dense plaques in smooth muscle. Apart from 
desmin expression in benign and malignant smooth and skeletal muscle 
tumours, myofibroblasts also express desmin positivity (Altmannsberger et al, 
1985). Desmin immunoreactivity in various spindle cell lesions, not 
traditionally considered to be of smooth muscle origin, has been interpreted 
as evidence of focal myofibroblastic differentiation, which include 
fibromatoses, malignant fibrous histiocytoma and myofibroblastoma of the 
breast (Enzinger and Weiss, 1995; Taccagni et al, 1997). 
2.4.6.1.3 VIMENTIN 
Vimentin is one of the five major types of cytoplasmic intermediate filaments, 
with a molecular weight of 57kDa (Rosai, 1996). Vimentin is ubiquitously 
expressed in all cells during early embryogenesis and is gradually replaced in 
many cells by type-specific intermediate filaments (Enzinger and Weiss, 
1983). In some mesenchymal tissues vimentin is co-expressed along with the 
type-specific intermediate filaments eg. desmin and vimentin co-expression in 
muscle cells (Enzinger and Weiss, 1983). Vimentin is so ubiquitous that 
some people use it as a control of the immunohistochemical reaction, in the 
sense of questioning its reliability if there is no staining for vimentin in the 
tissue. 
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3.0 PATIENTS AND METHODS 
3.1 INTRODUCTION 
The study has a 19 year retrospective component. The patient records and 
computer files of the Departments of Pathology and Plastic and 
Reconstructive Surgery, College of Health Sciences, University of Kwazulu-
Natal, Durban, were accessed to identify patients with Scar BCCs (SBCCs). 
The Department of Pathology has computerised surgical pathology records of 
all cases diagnosed in the Department from 1986. The scar BCCs included 
all BCCs arising in scars, with the scar being a significant finding, significant 
enough to have been included on the histopathology request form. Hence, 
the scar BCCs included BCCs arising in scars from a range of causes, but 
excluded scars occurring as a result of the previous excision. These scar 
BCCs are labelled "de novo scar BCCs" (DN-SBCCs). The second and third 
group of SBCCs encompass BCCs occurring in scar sites of previously 
excised BCCs. The scars had to be clinically and histologically prominent and 
the BCCs were non-destructive. Destructive, mutilating second BCCs 
occurring within scars were excluded from the study. The second group of 
SBCCs are referred to as "Regrowth scar BCCs" (RG-SBCCs) as they 
occurred in scars' occurring at sites of previously incompletely excised BCCs. 
The third group of SBCCs are referred to as "Recurrent scar BCCs" as they 
arose in scars occurring at sites of previously completely excised BCCs. 
3.2 DEFINITIONS AND REVIEW PARAMETERS 
3.2.1 CLINICAL PARAMETERS 
3.2.1.1 De novo Scar BCCs 
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BCCs that arise in areas of scarring from various causes. These may include 
scars induced by burns, trauma, vaccination, tattooing, chickenpox, leg ulcers 
or even hair transplantation. BCCs arising in scars induced by previous 
excision of cutaneous BCCs were excluded from this group. 
3.2.1.2 Regrowth BCCs 
BCCs that have been incompletely excised and have regrown at the same 
site, within scar tissue. 
3.2.1.3 Recurrent BCCs 
BCCs that have been completely excised with tumour free margins, but 
recurred at the same site, within scar tissue. 
3.2.2 HISTOLOGICAL PARAMETERS 
3.2.2.1 Histologic Growth Pattern 
3.2.2.1.1 Superficial BCC 
A BCC growth pattern in which small buds of proliferating basal cells grow 
down from the epidermis or hair follicle into the superficial dermis, whilst 
maintaining their attachment to the base of the epidermis. They present 
clinically as a patch or plaque resembling Bowen's disease or eczema. These 
patches slowly increase in size by peripheral extension. Superficial BCC 
occurs predominantly on the trunk. 
3.2.2.1.2 Nodular BCC 
A BCC growth pattern in which tumour cells grow in rounded masses with a 
prominent peripheral palisade of nuclei and may have a surrounding retraction 
artefact, due to retraction of fibrous stroma from the tumour mass. Nuclei lie 
in parallel alignment at right angles to those at the centre of the lobules 
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(peripheral palisading). The BCC may be differentiated or undifferentiated 
(solid). 
3.2.2.1.3. Micronodular BCC 
A variant of BCC in which small cell groups containing less than 50 cells and 
a less prominent peripheral palisade than nodular BCC. 
3.2.2.1.4 Infiltrative BCC 
Infiltrative BCCs are "hybrids" of the nodulocystic and morphoeaform 
varieties, in that they show a combination of expansile solidly cellular 
branched, sharply angulated, and linear cell groupings. The tumour cells in 
these lesions have been described as "spiky" by Jacobs et al (1982). 
Palisading is absent or poorly developed. 
3.2.2.1.5 Nodulocystic BCC 
A BCC presenting as a dome-shaped translucent papular nodule which may 
be variably fluid-filled. The nodule usually increases slowly in size and often 
undergoes central ulceration. 
3.2.2.1.6 Morphoeaform BCC 
The morphoeic subtype is a subgroup or variant of infiltrative BCC in which all 
the cell groups are small and irregular islands and cords of cells infiltrate into 
a dense, sclerotic, fibrous stroma. Appears as a sclerotic plaque or scar 
rather than a tumour, the borders are difficult to view clinically and the tumour 
may spread out beyond the obvious margins. This subtype of BCC is often 
not detected by the patient and physician at an early stage of development. 
3.2.2.1.7 Pigmented BCC 
The features and growth are similar to that of the nodulocystic subtype except 
for the presence of brown pigmentation. 
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3.2.2.1.8 Fibroepithelioma 
Commonly located on the back of patients, this type of BCC usually consists 
of one but occasionally of several raised, moderately firm nodules covered by 
smooth, slightly reddened skin. Clinically they resemble fibromas. 
3.2.2.1.9 Solid BCC 
Seen as an umbilicated pearly papule or nodule with rolled telangiectatic 
borders, there is often central necrosis. Microscopically, nests of basaloid 
cells are seen extending into the dermis with a palisade of cells at the 
periphery. The tumour is undifferentiated. 
3.2.2.1.10 Metatypical BCC 
The clinical appearance is not characteristic, but occasionally lesions are very 
extensive, ulcerated and grow rapidly. Histologically the tumour has features 
of BCC and squamous cell carcinoma. 
3.2.2.1.11 Basosebaceous BCC 
Rare subtype of BCC that expresses another line of ectodermal 
differentiation: the presence of mature sebaceous cells. 
3.3 Specimen Collection 
Histology case numbers were obtained from the records of the Departments 
of Pathology and Plastic and Reconstructive Surgery, College of Health 
Sciences, University of KwaZulu-Natal. In the Department of Pathology, a 
computer search using SNOMED classification codes was performed. All the 
relevant slides and wax blocks were retrieved from the Archives of the 
Department of Pathology and Regional Laboratory Services. Scar BCCs, 
initial biopsies with subsequent regrowth and recurrent BCCs were included in 
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the study. Recurrent and regrowth BCCs in which the original biopsy could 
not be traced were also used provided that the original reports commented on 
the excision margins. Slides that were faded or damaged were re-cut from 
the paraffin wax embedded tissue blocks. 3pm sections were cut, stained 
with routine Mayer's haematoxylin and eosin and then viewed by light 
microscopy. 
3.4 Clinical Data 
The following clinical details, extracted from the files of Pathology and Plastic 
and Reconstructive Surgery were documented: patient name, age, gender, 
race, site of lesion, size of specimen, size of lesion, clinical diagnosis and 
histology number. 
3.5 Histological Data 
A range of histologic parameters were assessed and qualitatively evaluated 
as described by Dixon et a/(1989) and Jacobs et a/(1982). 
3.5.1 Growth pattern 
The growth pattern was classified into four groups, namely, included 
superficial, nodular, micronodular and infiltrative groups. A predominant 
subtype referred to a BCC with >60% constitution of a particular pattern. 
3.5.2 Palisade 
Refers to the roughly parallel alignment of the peripheral nuclei at right angles 
to those in the center of the tumour nodules and to the basement membrane. 
3.5.3 Cell group shape 
The cell group shape was recorded as round or spiky. 
3.5.3.1 Cell group shape: round 
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Tumours classified as round were composed entirely of cell nests with a 
round, smooth configuration. 
3.5.3.2 Cell group shape: spiky 
Tumours composed entirely of cell nests with a jagged, irregular outline. 
3.5.4 Peritumoural lacunae formation 
This refers to the separation of the tumour from its stroma, with the formation 
of lacunae (or clefts), which may contain necrotic cells and pyknotic nuclei. 
3.5.5 Invasion 
Tumour invasion was assessed in terms of the micro-anatomic extent of 
disease and was categorized as follows: 
Extension into the upper reticular dermis. 
Extension into the deep reticular dermis. 
Extension into subcutaneous tissue. 
Extension into muscle. 
Perineurial invasion. 
3.5.6 Perineural lymphocytes 
Were noted as present or absent. 
3.5.7 Differentiation 
The tumour was classified as differentiated or undifferentiated. When 
differentiation was present, the type of differentiation was recorded. 
3.5.8 Mitoses 
Mitotic figure that has a tripolar or tetrapolar form. Mitoses with the 
characteristic morphology as seen during the mitotic cycle were regarded as 
typical, but tripolar forms were regarded as "atypical". 
3.5.9 Apoptosis 
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Apoptosis was identified as cells with condensed, eosinophilic cytoplasm 
containing nuclear fragments. 
3.5.10 Cell shape 
The cell shape was classified as either polygonal, elongated or spindled 
shape. 
3.5.11 Inflammatory host response 
The presence of lymphocytes and/or plasma cells at the tumour stroma 
interface or within the tumour. 
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3.6 IMMUNOHISTOCHEMICAL STUDIES 
3.6.1 PRIMARY ANTIBODIES USED 
FROM: Signet Pathology Systems, Inc., Dedham, MA. 
Desmin 
(prediluted antibody, Clone D33; 1:3, monoclonal mouse 
antibody). 
Vimentin 
prediluted antibody, Clone V9; 1:40, monoclonal mouse 
antibody). 
FROM: Novocastra Laboratories Ltd, Benton Lane, U.K. 
bcl-2 
(lyophillised, reconstituted with 1ml Phosphate buffered saline 
(PBS), Clone bcl-2100/D5, 1:40, monoclonal mouse antibody). 
Laminin 
(lyophillised, reconstituted with 0.1ml PBS, Clone Lam 89, 
1:200, monoclonal mouse antibody). 
FROM: DAKO A/S Glostrup, Denmark. 
Anti-Human Ki-67 Antigen 
(prediluted antibody, Clone MIB1, 1:40, monoclonal mouse 
antibody). 
Anti-Human p53 Protein 
prediluted antibody, Clone DO-7, 1:100, monoclonal mouse 
antibody). 
Anti-Human Fibronectin 
prediluted antibody, Code No.A0245, 1:400, rabbit antibody). 
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FROM: Dako Corporation, Carpinteria, USA 
Anti-Human muscle Actin 
(prediluted antibody, Clone HHF35, 1:50, monoclonal mouse 
antibody). 
3.6.2 UNIVERSAL KIT 
FROM: Dako Corporation, Carpinteria, USA 
Dako LSAB2 System, HRP Kit 
The labeled streptavidin-biotin (LSAB) method was used for 
immunohistochemical studies, which was designed for use with primary 
antibodies from rabbit and mouse. The kit consists of Link (110ml), which is 
composed of biotinylated anti-rabbit and anti-mouse immunoglobulins in 
phosphate buffered saline (PBS) containing a carrier protein and 15mM 
sodium azide and streptavidin peroxidase in PBS, containing a carrier protein 
and anti-microbial agent. 
3.6.3 SAMPLE PREPARATION FOR IMMUNOHISTOCHEMISTRY 
1. Tissue sections were cut at 2uM thickness using sterile disposable 
blades on a rotary microtome. 
2. They were floated onto a water bath and picked on poly-L-lysine 
coated slides, (see Appendix C). 
3. The sections were baked on a hotplate at 60°C for 20mins before 
dewaxing by agitating in two changes of xylene (3minut.es in each). 
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4. This was followed by passage through two changes of 100% alcohol 
for 3 minutes each and two changes of 95% alcohol for 3 minutes 
each. 
5. The sections were re-hydrated in running tap water for 5 minutes. 
6. Antigen retrieval using the microwave, or enzyme pretreatment (see 
Appendix A) was then performed. 

















Enzyme pretreatment (protease) 
Enzyme pretreatment (pronase) 
3.6.4 PROCEDURE FOLLOWING ANTIGEN RETRIEVAL 
3.6.4.1 Following antigen retrieval using the microwave technique. 
1. Slides were allowed to cool at room temperature for 5 minutes. 
2. Slides were then washed in tap water for 1 minute. 
3. Slides were incubated in 3% hydrogen peroxide (see Appendix B) in a 
coplin jar at room temperature for 5 minutes. 
4. Slides were washed in tap water. 
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5. A circle was drawn around tissue sections with a Dako pen (Dako A/S, 
Glostrup, Denmark) to form a well for reagents on the slide. Slides 
were then placed in PBS. 
6. Excess PBS buffer was removed from slide. 
7. Primary antibody (at the correct dilution) was added. 
8. The slides were then incubated in a Sharp Carousel microwave at 
"LOW" temperature for 4 minutes and 30 seconds. 
9. The slides were then rinsed three times with PBS. 
10. Excess PBS was removed. 
11. Link antibody was applied to the sections. 
12. The slides were then incubated in a Sharp Carousel microwave at 
"LOW" temperature for 3 minutes and 30 seconds. 
13. The slides were then rinsed three times with PBS. 
14. Excess PBS was removed. 
15. Label antibody was then applied to the tissue sections. 
16. The slides were then incubated in a Sharp Carousel microwave at 
"LOW" temperature for 3 minutes and 30 seconds. 
17. The slides were then rinsed three times with PBS and excess PBS was 
tapped off. 
18. DAB-chromogen solution (see APPENDIX B) was applied to the slides. 
Colour development was observed microscopically. 
3.6.4.2 Procedure following antigen retrieval using the enzyme 
pretreatment technique 
3.6.4.2.1 Following Protease pretreatment: Laminin immunostaining 
1. The slides were rinsed in water. 
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2. Slides were then quenched in methanol/hydrogen peroxide for 30 
minutes. 
3. The slides were then rinsed in PBS. 
4. Normal horse serum (5% in PBS) was then applied to the sections for 
20 minutes at room temperature. 
5. Monoclonal antibody (1:200) was applied to the sections and then 
incubated in a Sharp Carousel microwave at "LOW" temperature for 4 
minutes and 30 seconds, and then allowed to stand at room 
temperature for 50 minutes. 
6. The slides were then rinsed three times with PBS. 
7. Excess PBS was removed. 
8. Link antibody was applied to the sections. 
9. The slides were then incubated in a Sharp Carousel microwave at 
"LOW" temperature for 3 minutes and 30 seconds. 
10. The slides were then rinsed three times with PBS. 
11. Excess PBS was removed. 
12. Label antibody was then applied to the tissue sections. 
13. The slides were then incubated in a Sharp Carousel microwave at 
"LOW" temperature for 3 minutes and 30 seconds. 
14. The slides were then rinsed three times with PBS and excess PBS was 
tapped off. 
15. DAB-chromogen solution (APPENDIX B) was applied to the slides. 
Colour development was observed microscopically. 
3.6.4.2.2 Following Pronase pretreament: Fibronectin 
immunostaining (use 3% BSA for all dilutions) 
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1. The slides were rinsed in water. 
2. Normal horse serum (5% in PBS) was then applied to the sections for 
20 minutes at room temperature. 
3. Monoclonal antibody (1:400) was applied to the sections and then 
incubated in a Sharp Carousel microwave at "LOW" temperature for 4 
minutes and 30 seconds, and then allowed to stand at room 
temperature for 50 minutes. 
4. The slides were then rinsed in PBS. 
5. Excess PBS was removed. 
6. Link antibody was applied to the sections. 
7. The slides were then incubated in a Sharp Carousel microwave at 
"LOW" temperature for 3 minutes and 30 seconds. 
8. The slides were then rinsed three times with PBS. 
9. Excess PBS was removed. 
10. Label antibody was then applied to the tissue sections. 
11. The slides were then incubated in a Sharp Carousel microwave at 
"LOW" temperature for 3 minutes and 30 seconds. 
12. The slides were then rinsed three times with PBS and excess PBS was 
tapped off. 
13. DAB-chromogen solution (APPENDIX B) was applied to the slides. 
Colour development was observed microscopically. 
3.6.5 Procedure following DAB colour development 
1. The slides were left in running tap water for 5 minutes. 
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2. The sections were then counterstained in Mayer's haematoxylin (see 
APPENDIX B) for one minute. 
3. The slides were washed in running tap water for 2 minutes. 
4. The slides were then immersed in ammoniated water (see APPENDIX 
B) to develop the counterstain. 
5. The slides were rinsed in running tap water for 2 minutes. 
6. The sections were then dehydrated in two changes of 90% alcohol (2 
minutes each) and 2 changes of absolute ethanol (3 minutes each). 
7. The sections were then cleared in two changes of xylene for 3 minutes 
each. 
8. The sections were mounted using DPX and coverglass. 
3.6.6 SCORING OF IMMUNOHISTOCHEMICAL STAINING 
3.6.6.1 Epithelial component 
Ki-67, p53 and bcl-2 immunostaining was scored as follows: 
Negative: No staining of cells 
0: £ 5% of cells positive 
1 +: 6-25% of cells positive 
2+: 26-50% of cells positive 
3+: 51-75% of cells positive 
4+: 76-100% of cells positive 
These scores were obtained by counting the number of positive cells and 
expressing this as a percentage of the total number of cells present in a high 
power field (X40). A maximum of 10 high power fields was counted and an 
average was calculated. 
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3.6.6.2 Stromal component 
3.6.6.2.1 Laminin immunostaining 
0: All cell groups with intact basement membrane 
1 +: 1 -25% of cell groups with basement membrane discontinuity 
2+: 26-50% of cell groups with basement membrane discontinuity 
3+: 51-75% of cell groups with basement membrane discontinuity 
4+: 76-100% of cell groups with basement membrane discontinuity 
3.6.6.2.2 Fibronectin 
0: Fibronectin present around <5% of tumour cell groups 
1 +: Fibronectin present around 6-25% of tumour cell groups 
2+: Fibronectin present around 26-50% of tumour cell groups 
3+: Fibronectin present around 51 -75% of tumour cell groups 
4+: Fibronectin present around 76-100% of tumour cell groups 
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4.0 RESULTS 
4.1 SAMPLE 
Seventy three patients with scar BCCs were accessed from the files of 
Pathology and Plastic and Reconstructive Surgery. A total of 81 completely 
excised BCCs formed the study cohort. There were 29 de novo scar BCCs 
(DN-SBCCs), 27 regrowth scar BCCs (RG-SBCCs) and 25 recurrent scar 
BCCs (R-SBCCs). The initial excision biopsies of 8 RG-SBCCs and 7 R-
SBCCs were also analysed. 
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TABLE 1: Clinical details of Scar BCCs. 
The nose was commonest head and neck site that was involved by DN-
SBCCs and RG-SBCCs. The cheek and ear were the commonest sites of R-
SBCC involvement. In the periorbital area, the left eye-lid was involved by 
DN-SBCCs in 2 (7%) patients and the lateral canthus in 1 (3%). R-SBCCs of 
the periorbital involved the right lower eyelid (1 patient) and left medial 
canthus (1 patient). 
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The smallest DN-SBCC and RG-SBCC measured 1 x 1mm and 3 x 4mm 
each, respectively. The largest DN-SBCC measured 15 x 15mm. Nineteen 
DN-SBCCs were <15mm in largest diameter. The largest RG-SBCC and R-
SBCC measured 45 x 60mm and 30 x 10mm each, respectively. Ten R-
SBCCs measured <20mm. 
4.3 HISTOLOGICAL DETAILS 
4.3.1 Growth Patterns 
























Table 2: Growth patterns of DN-SBCCs, RG-SBCCs and R-SBCCs 
Key: 
N = Nodular 
M = Micronodular 
S = Superficial 
I = Infiltrative 












Table 3: Summary of growth patterns of DN-SBCCs, RG-SBCCs and R 
SBCCs 
(Plates 1-14) 
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In 28 (97%) DN-SBCCs a predominant BCC subtype was identified while in 1 
a pure nodular subtype was evident (tables 2-3). All RG-SBCCs and R-
SBCCs demonstrated a predominance of one histological subtype (table 2). 






















Table 4: RG-SBCCs: Growth patterns of initial and second tumours 
A pure nodular pattern was seen in 1 (12%) initial RG-SBCC. Of those RG-
SBCCs with a predominantly nodular growth pattern, the majority had minor 
micronodular and infiltrative patterns. One initial RG-SBCC that had a 
predominantly infiltrative growth pattern also contained minor superficial, 
nodular and micronodular growth patterns. In all initial biopsies with a 
combination of architectural patterns, the superficial, micronodular and 
nodular components were situated higher in the dermis than the infiltrative 
components. Similarly, in the second biopsy of RG-SBCC, the majority of 
tumours had a predominantly nodular pattern and minor micronodular and 
infiltrative patterns. 
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Table 5: R-SBCC: Growth patterns of initial and second tumours' 
Of those R-SBCCs with a predominantly nodular growth pattern, the majority 
had minor micronodular and infiltrative patterns. One initial R-SBCC that had 
a predominantly infiltrative growth pattern also contained a minor nodular 
growth pattern. The majority of R-SBCCs with a predominantly nodular 
pattern had minor superficial, micronodular or infiltrative patterns. 













































Table 6: Extent of invasion in DN-SBCCs, RG-SBCCs and R-SBCCs 
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Only 1 (4%) BCC extended into muscle. Five (17%) DN-SBCCs had 
incompletely excised lateral margins and 4 (14%) incompletely excised deep 
margins. All initial RG-SBCCs had incompletely excised lateral margins. The 
lateral and deep margins of all initial R-SBCCs were clear of tumour. 
4.3.3 Architectural contour, palisade formation and peritumoural 
lacunae. 
The superficial, nodular and micronodular growth patterns of all DN-SBCCs, 
RG-SBCCs and R-SBCCs showed palisade formation. These patterns also 
demonstrated smooth, rounded contours, while the infiltrative component had 
a spiky configuration. One (3%) DN-SBCC lacked peritumoural lacunae; 3 
(11%) had focal and 25 (86%) had prominent peritumoural lacunae. All initial 
biopsies of RG-SBCCs had prominent peritumoural lacunae. Six (22%) RG-
SBCCs lacked peritumoural lacunae; 2 (7%) had focal and 19 (71%) had 
prominent peritumoural lacunae. One (14%) initial R-SBCC had focal and 6 
(86%) had prominent peritumoural lacunae. Four (16%) R-SBCCs lacked 
peritumoural lacunae; 2 (8%) had focal and 19 (76%) had prominent 
peritumoural lacunae. 
4.3.4 Differentiation 
Sixteen (55%) DN-SBCCs showed adenoid and keratotic differentiation, 5 
(17%) showed exclusive adenoid and 8 (28%) exclusive keratotic 
differentiation. Four (50%) initial biopsies of RG-SBCCs showed adenoid and 
keratotic differentiation. Thirteen (48%) RG-SBCCs showed adenoid and 
keratotic differentiation; while 5 (19%) and 2 (7%) showed exclusive adenoid 
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and keratotic differentiation, respectively. Seven (26%) RG-SBCCs were 
undifferentiated. Four (57%) initial R-SBCCs showed adenoid and keratotic 
differentiation; one (14%) showed adenoid differentiation only and two (29%) 
were undifferentiated. Eleven (44%) R-SBCCs showed adenoid and keratotic 
differentiation; 5 (20%) showed adenoid differentiation only and 6 (24%) 
showed keratotic differentiation only. Three (12%) R-SBCCs were 
undifferentiated. 
4.3.5 Cellular details 
The superficial, nodular and micronodular growth patterns had polygonal to 
elongated cells in all 3 BCC groups, while the infiltrative component had 
spindle shaped cells. Giant cells and pseudoinclusions were present in one 
(3%) DN-SBCC and one (4%) RG-SBCC. Twenty six (90%) DN-SBCCs 
demonstrated focal clear cell change, while 4 (50%) initial RG-SBCCs 
demonstrated the same. Nineteen (70%) RG-SBCCs had focal clear cells. 
Three (43%) initial and 19 (76%) R-SBCCs had focal clear cells. In 2 (8%) R-
SBCCs clear cells were prominent. Vesicular nuclei were seen in 26 (90%) 
DN-SBCCs. Six (75%) initial and all RG-SBCCs contained vesicular nuclei. 
Vesicular nuclei were seen in all initial and R-SBCCs. Nucleoli were 
conspicuous in 26 (90%) DN-SBCCs. Nucleoli were conspicuous in 5 (63%) 
initial and 20 (74%) RG-SBCCs. Nucleoli were conspicuous in 6 (86%) initial 
and 21 (84%) R-SBCCs. Mitoses and apoptotic figures were present and 
prominent in all BCCs. 
4.3.6 Stromal features 
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In DN-SBCCs, fibrosis was present in advancing front of the tumour in all 
cases. In 13/29 DN-SBCCs fibrosis was confined to the upper reticular 
dermis (URD). Sixteen of 29 DN-SBCCs demonstrated fibrosis in the 
advancing front of the tumour in the URD and deep reticular dermis (DRD). 
The majority of DN-SBCCs showed solar elastotic masses (SEM) in the DRD 
(21/29), while 7/29 DN-SBCCs showed SEM in the URD. Only 1 case did not 
show any SEM. 
Nineteen of 27 RG-SBCCs showed fibrosis around (URD and DRD) the 
tumour. Five showed fibrosis in the DRD in the advancing front of the tumour. 
One each had fibrosis in the advancing front of the tumour, localized to the 
URD and DRD. One RG-SBCC demonstrated fibrosis within but not around 
the tumour. Twenty of 27 RG-SBCCs showed SEM around the tumour and 5 
RG-SBCCs showed SEM in the DRD. Two RG-SBCCs did not show any 
SEM. All of 25 R-SBCCs demonstrated fibrosis in the advancing front, 
localized to the DRD in 24/25 and to the URD in 1/25 cases. SEM was 
present in the DRD in 24/25 biopsies and in the URD in 1/25 case. 


























TABLE 7: Hyalinisation, stromal spindle cells and haemosiderin 
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Hyalinisation and stromal spindle cells were seen in the majority of the DN-
SBCCs, while haemosiderin was demonstrated in 7 (24%) tumours. None of 
the initial biopsies of RG-SBCCs or R-SBCCs demonstrated haemosiderin. 
The majority of RG-SBCCs and R-SBCCs had hyalinisation and stromal 
spindle cells. Five (17%) and 2 (8%) RG-SBCCs and R-SBCCs 
demonstrated haemosiderin, respectively. Capillaries, lymphocytes and 
plasma cells were present at the tumour-stroma interface and within the 
fibrotic component of all BCCs. 
4.3.8 Nerve involvement 
Perineural lymphocytes were present in 23 (79%) DN-SBCCs and perineurial 
tumour invasion was seen in 3 (10%) DN-SBCCs. Perineural lymphocytes 
were present in 2 (25%) and perineurial invasion was present in 1 (13%) initial 
biopsies of RG-SBCC. Perineural lymphocytes were present in 16 (59%) and 
perineurial tumour invasion was seen in 7 (26%) RG-SBCCs. Perineural 
lymphocytes were present in 2 (8%) initial biopsies of R-SBCCs, while no 
perineurial invasion was seen. Perineural lymphocytes were present in 16 
(64%) and perineurial tumour invasion was seen in 6 (24%) R-SBCCs. 
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Table 8: Laminin discontinuity in DN-SBCCs, RG-SBCCS and R-
SBCCs 
4.4.1.1 Laminin discontinuity in ON-SBCCs, RG-SBCCs and R-
SBCCs 
(Plates 15-23) 
Twenty seven (93%) of 29 DN-SBCCs showed intact basement membrane 
laminin staining around tumour cell nests, while 2/29 (7%) showed 1+ and 2+ 
loss of basement membrane laminin. This was present in areas containing 
lymphocytes at the tumour-stroma interface. Twenty four (89%) of 27 RG-
SBCCs showed intact basement membrane laminin staining around tumour 
cell nests, while 3/27 (11%) RG-SBCCs showed 2+ or 3+ basement 
membrane laminin discontinuity in infiltrative foci. Twenty three (92%) of 25 
R-SBCCs showed intact basement membrane laminin staining around tumour 
cell nests, while 2/25 (8%) showed 2+ basement membrane laminin 
discontinuity in infiltrative foci. Comparison of the basement membrane 
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laminin staining pattern in DN-SBCCs, RG-SBCCs and R-SBCCs did not 
reveal any statistically significant results (p=1.0). 























Table 9: Laminin discontinuity of initial and second RG-SBCCs 
All of eight (100%) initial and RG-SBCCs showed intact basement membrane 
laminin staining around the tumour cell nests. Comparison of the basement 
membrane laminin staining pattern in the initial and RG-SBCCs did not reveal 
any statistically significant results (p=1.0). 
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Table 10: Laminin discontinuity of initial and second R-SBCCs 
All of seven (100%) initial and RG-SBCCs showed intact basement 
membrane laminin staining around the tumour cell nests. Comparison of the 
basement membrane laminin staining pattern in the initial and R-SBCCs did 






1 2 3 4 
• DN-SBCCs 14 8 5 2 
• RG-SBCCs 9 5 9 4 
D R-SBCCs 14 5 3 3 
Table 11: Fibronectin immunopositivity in DN-SBCCs, RG-SBCCs and R-
SBCCs 
4.4.2.1 Peritumoural fibronectin immunopositivity in DN-SBCCs, RG-
SBCCs and R-SBCCs 
(Plates 24-32) 
Seven (24%) of 29 DN-SBCCs showed high (>2+) peritumoural fibronectin 
immunopositivity, while 22/29 (76%) showed low (^2+) peritumoural 
fibronectin immunopositivity. Thirteen (48%) of 27 RG-SBCCs showed high 
(>2+) and 14/27 (52%) showed low (<2+) peritumoural fibronectin 
immunopositivity. Six (24%) of 25 R-SBCCs showed high (>2+) peritumoural 
fibronectin immunopositivity, while 19/25 (76%) R-SBCCs showed low (<2+) 
peritumoural fibronectin immunopositivity. Comparison of fibronectin staining 
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Table 14: Actin immunopositivity in DN-SBCCs, RG-SBCCs and R-
SBCCs. 
(Plates 33-45) 
4.4.3.1 Actin immunopositivity in DN-SBCCs, RG-SBCCs and R-SBCCs. 
Five (17%) of 29 DN-SBCCs showed focal epithelial actin immunopositivity. 
None demonstrated stromal actin immunopositivity. Three RG-SBCCs 
demonstrated focal epithelial actin immunopositivity in the infiltrative 
component only, 2 demonstrated exclusive stromal actin immunopositivity and 
2 demonstrated epithelial and stromal actin immunopositivity. The stromal 
and epithelial components in 20/27 (75%) RG-SBCCs were actin 
immunonegative. Three of 25 (12%) R-SBCCs showed actin 
immunopositivity; two showed focal epithelial and stromal actin 
immunopositivity and one showed stromal actin immunopositivity exclusively. 
Twenty two (88%) of 25 R-SBCCs were actin negative. Comparison of 
stromal actin staining (low [<2+] versus high [>2+] staining) in DN-SBCCs and 
RG-SBCCs (p=0.42), DN-SBCCs and R-SBCCs (p=0.71), and, RG-SBCCs 
and R-SBCCs (p=0.29) revealed no statistical significance. 
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(low [<2+] versus high [>2+] staining) in DN-SBCCs and RG-SBCCs (p=0.06), 
DN-SBCCs and R-SBCCs (p=0.99), and, RG-SBCCs and R-SBCCs (p=0.07) 
revealed no statistical significance. All demonstrated focal intratumoural 
fibronectin immunopositivity. 




























Table 12:Fibronectin immunopositivity of initial and second RG-SBCCs 
Five (62%) of 8 initial RG-SBCCs showed low (<2+) and 3/8 (38%) showed 
high (>2+) peritumoural fibronectin immunopositivity. Six (75%) of 8 RG-
SBCCs showed low (^2+) peritumoural fibronectin immunopositivity and 2/8 
(25%) showed high (>2+) peritumoural fibronectin immunopositivity. 
Comparison of the fibronectin staining pattern in the initial and RG-SBCCs did 
not reveal any statistically significant results (p=0.7). 
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Fibronectin immunopositivity of initial and second R-
Six (86%) of 7 initial R-SBCCs showed low (<2+) and 1/7 (14%) showed high 
(>2+) peritumoural fibronectin immunopositivity. All of 7 (100%) R-SBCCs 
showed low (^2+) peritumoural fibronectin immunopositivity. Comparison of 
the fibronectin staining pattern in the initial and R-SBCCs did not reveal any 
statistically significant results (p=1.0). 
4.4.3 ACTIN(MSA) 
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Table 14: Actin immunopositivity in DN-SBCCs, RG-SBCCs and R-
SBCCs. 
(Plates 33-45) 
4.4.3.1 Actin immunopositivity in DN-SBCCs, RG-SBCCs and R-SBCCs. 
Five (17%) of 29 DN-SBCCs showed focal epithelial actin immunopositivity. 
None demonstrated stromal actin immunopositivity. Three RG-SBCCs 
demonstrated focal epithelial actin immunopositivity in the infiltrative 
component only, 2 demonstrated exclusive stromal actin immunopositivity and 
2 demonstrated epithelial and stromal actin immunopositivity. The stromal 
and epithelial components in 20/27 (75%) RG-SBCCs were actin 
immunonegative. Three of 25 (12%) R-SBCCs showed actin 
immunopositivity; two showed focal epithelial and stromal actin 
immunopositivity and one showed stromal actin immunopositivity exclusively. 
Twenty two (88%) of 25 R-SBCCs were actin negative. Comparison of 
stromal actin staining (low [<2+] versus high [>2+] staining) in DN-SBCCs and 
RG-SBCCs (p=0.42), DN-SBCCs and R-SBCCs (p=0.71), and, RG-SBCCs 
and R-SBCCs (p=0.29) revealed no statistical significance. 
4.4.3.2 Initial versus second RG-SBCCs 
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Table 15: Actin immunopositivity of initial and RG-SBCCs 
All of 8 initial and RG-SBCCs were actin negative. Comparison of the actin 
staining pattern in the initial and RG-SBCCs did not reveal any statistically 
significant results (p=1.0). 
4.4.3.3 Initial versus second R-SBCCs 
Table 16: 
SBCCs 
Actin immunopositivity of initial and second R-
All of 7 initial and R-SBCCs were actin negative. Comparison of the actin 
staining pattern in the initial and R-SBCCs did not reveal any statistically 
significant results (p=1.16). 
4.4.4 DESMIN 
4.4.4.1 Desmin immunoreactivity 
(Plates 46-48) 
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No desmin immunoreactivity was demonstrated in the epithelial or stromal 
components of DN-SBCCs, RG-SBCCs and R-SBCCs. Desmin 
immunopositivity in vascular smooth muscle served as an inbuilt control. 
4.4.5 VIMENTIN 
4.4.5.1 Vimentin immunoreactivity 
Plates (49-58) 
All the BCC groups showed 3+ or 4+ stromal vimentin immunopositivity. 
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4.5 IMMUNOHISTOCHEMICAL STUDIES: PROLIFERATION MARKER 






0 1 2 3 4 
D DN-SBCCs 1 8 16 4 0 
• RG-SBCCs 7 8 10 2 0 
DR-SBCCs 4 5 16 0 0 
Table 17: MIB1 immunopositivity in DN-SBCCs, RG-SBCCs and R-
SBCCs 
(Plates 59-78) 
4.5.1.1 MIB1 immunopositivity in DN-SBCCs, RG-SBCCs and R-
SBCCs 
The immunopositive signal varied from pale to bright in different parts of an 
individual tumour. In some tumours there was peripheral immunopositivity, in 
some, central, and in others, peripheral and central immunopositivity. Four 
(14%) of 29 DN-SBCCs showed high (>2+) immunostaining (Plate K1), while 
25/29 (86%) showed low (<2+) MIB1 immunopositivity (Plate K2). Two (7%) 
of 27 RG-SBCCs showed high (>2+) MIB1 immunopositivity (Plate K3), while 
25/27 (93%) showed low (<2+) (Plate K4) MIB1 immunopositivity. All of 25 R-
SBCCs showed low (^2+) MIB1 immunopositivity. Immunopositive cells were 
randomly distributed, in the peripheral palisade of cells as well as centrally 
within the cell nests, in all the DN-SBCCs, RG-SBCCs and R-SBCCs. Focal 
infiltrative foci demonstrated accentuated MIB1 staining at the tumour-stroma 
interface. Comparison of MIB1 staining (low [<2+] versus high [>2+] staining) 
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in DN-SBCCs and RG-SBCCs (p=0.67), DN-SBCCs and R-SBCCs (p=0.11), 
and, RG-SBCCs and R-SBCCs (p=0.49) revealed no statistical significance. 























Table 18: MIB1 immunopositivity of initial and second RG-SBCCs 
Seven (88%) of 8 initial RG-SBCCs showed low (<2+) MIB1 immunopositivity, 
while 1/8 (12%) showed high (>2+) MIB1 immunopositivity. Seven (88%) of 8 
RG-SBCCs demonstrated low (<2+) MIB1 immunopositivity, while 1/8 (12%) 
showed high (>2+) MIB1 immunopositivity. Comparison of the MIB1 staining 
pattern in the initial and RG-SBCCs did not reveal any statistically significant 
results (p=0.55). 
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Table 19: MIB1 immunopositivity of initial and second R-SBCCs 
All of the initial and R-SBCCs demonstrated low (^2+) MIB1 immunopositivity. 
Comparison of the MIB1 staining pattern in the initial and R-SBCCs did not 
reveal any statistically significant results (p=1.0). 
4.5.2 Cell cycle proteins 























Table 20: p53 immunopositivity in DN-SBCCs, RG-SBCCs and R-
SBCCs. 
4.5.2.2 p53 immunopositivity in DN-SBCCs, RG-SBCCs and R-SBCCs. 
(Plates 79-99) 
p53 immunostaining was nuclear and randomly distributed in the tumour cell 
nests in all cases. The immunopositive signal varied from pale to bright. 
Twelve (41%) of 29 DN-SBCCs showed high (>2+) p53 immunostaining, while 
17/29 (59%) showed low (<2+) p53 immunostaining. Sixteen (59%) of 27 RG-
SBCCs showed low (<2+) p53 immunostaining, while 11/27 (41%) showed 
high (>2+) p53 immunostaining. Thirteen (52%) R-SBCCs showed low (<2+) 
p53 immunostaining and 12/25 (48%) R-SBCCs showed high (>2+) p53 
immunostaining. Comparison of p53 staining (low [<2+] versus high [>2+] 
staining) in DN-SBCCs and RG-SBCCs (p=0.96), DN-SBCCs and R-SBCCs 
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(p=0.62), and, RG-SBCCs and R-SBCCs (p=0.59) revealed no statistical 
significance. 


















Table 21: p53 immunopositivity of initial and second RG-SBCCs 
Two (25%) of 8 initial RG-SBCCs showed high (>2+) p53 immunopositivity, 
while 6/8 (75%) showed low (<2+) p53 immunopositivity. Five (63%) of 8 RG-
SBCCs showed low (^2+) p53 immunostaining, while 3/8 (37%) showed high 
(>2+) p53 immunostaining. Comparison of p53 staining pattern in the initial 
and RG-SBCCs did not reveal any statistically significant results (p=0.42). 
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Table 22: p53 immunopositivity of initial and second R-SBCCs 
Two (29%) of 7 intial R-SBCCs showed high (>2+) and 5/7 (71%) showed low 
(<2+) p53 immunopositivity. Five of 7 (72%) R-SBCCs showed low (<2+) and 
2/7 (28%) showed high (>2+) p53 immunostaining. Comparison of the p53 
staining pattern in the initial and R-SBCCs did not reveal any statistically 
significant results (p=0.42). 

































Table 23: bcl-2 immunopositivity in DN-SBCCs, RG-SBCCs and R-
SBCCs. 
4.5.3.1 bcl-2 immunopositivity in DN-SBCCs, RG-SBCCs and R-
SBCCs. 
(Plate 100-117) 
Twenty four (83%) of 29 DN-SBCCs showed high (>2+) bcl-2 
immunopositivity, while 5/29 (17%) showed low (^2+) bcl-2 immunopositivity. 
Twenty (74%) of 27 RG-SBCCs showed high (>2+) bcl-2 immunopositivity, 
while 7/27 (26%) showed low (<2+) bcl-2 immunopositivity. Eighteen (72%) of 
25 R-SBCCs showed high (>2+) bcl-2 immunopositivity, while 7/25 (28%) 
showed low (^2+) bcl-2 immunopositivity. Comparison of bcl-2 staining (low 
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[<2+] versus high [>2+] staining) in DN-SBCCs and RG-SBCCs (p=0.42), DN-
SBCCs and R-SBCCs (p=0.34), and, RG-SBCCs and R-SBCCs (p=0.86) 
revealed no statistical significance. 


























Table 24: bcl-2 immunopositivity of initial and second RG-SBCCs 
Seven (88%) of 8 initial RG-SBCCs showed high (>2+) bcl-2 
immunopositivity, while one (12%) showed low (^2+) bcl-2 immunopositivity. 
Seven (88%) of 8 RG-SBCCs showed high (>2+) bcl-2 immunopositivity, 
while 1/8 (12%) showed low (^2+) bcl-2 immunopositivity. Comparison of the 
bcl-2 staining pattern in the initial and RG-SBCCs did not reveal any 
statistically significant results (p=0.64). 
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Table 25: bcl-2 immunopositivity of initial and second R-SBCCs 
Five (72%) of 7 initial R-SBCCs showed high (>2+) bcl-2 immunopositivity, 
while 2 (28%) showed low (<2+) bcl-2 immunopositivity. All of 7 (100%) R-
SBCCs showed high (>2+) bcl-2 immunopositivity. Comparison of the bcl-2 
staining pattern in the initial and R-SBCCs did not reveal any statistically 
significant results (p=1.0). 
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5.0 DISCUSSION 
5.1 Histological features of S-BCCs 
In 1828, Jean-Nicolas Marjolin described malignant ulceration in chronic scars 
(Bostwick et al, 1976). Subsequently, a detailed description of this evolution 
was described, and the entity was labelled "Marjolin's ulcer" (Celikoz et al, 
1997). The exact incidence of carcinogenesis in cutaneous scars is 
undetermined. However, while Broders (1921) estimated that 24% of all 
extremity cancers arose in scars, Schrek (1941) reported an 18% incidence of 
scar cancers in the scalp, trunk, legs and arms. Squamous cell carcinomas 
are the most common, and BCCs, the second most common malignancy in 
wounds (Kowal-Vern and Criswell, 2005). While scar formation is a distinct 
process in malignant tumours, it is controversial whether the scar predisposes 
to or follows carcinogenesis (Warren, 1943). In the present study, 66% of 
BCCs occurring within scars demonstrated a predominantly nodular growth 
pattern. However 69% of DN-SBCCs contained an infiltrative subtype as a 
predominant (13%) or minor (56%) component. A micronodular component 
was present in 58% of DN-SBCCs as a predominant (3%) or minor (55%) 
subtype. Aggressive infiltrative and micronodular histologic growth patterns 
were therefore identified in 92% of DN-SBCCs in the present study, 
confirming the findings of several workers that BCCs within scars may contain 
histologically aggressive subtypes. The exact pathogenetic mechanism 
underlying the aggressive infiltrative and micronodular morphology in DN-
SBCCs is uncertain. Speculated hypotheses include aggressive and 
pseudoaggressive phenotypic features in an altered milieu (Swetter et al, 
1998). The former is speculated to be induced by matrix metalloproteinases 
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at sites of wound healing, while the latter is hypothesized to be a function of 
"tracks" along collagen and fibrous tissue, formed within the healing scar 
(Swetter et al, 1998). While the pseudoaggressive phenotypic hypothesis is 
applicable to DN-SBCCs in the present study since none recurred after 
complete excision, assessment of the tumour biology, especially cellular 
proliferation and stromal characteristics, may play a pivotal role in confirming 
this theory. The role, significance and impact of the scar in R-SBCCs and 
RG-SBCCs, however, appear multifaceted and more complex. Scar cancers 
of the lung, that show little elastin, are usually associated with areas of 
proliferating spindle cells (fibroblasts). Such scarring is usually seen in 
carcinomas with invasive or destructive growth and occurs randomly 
throughout the tumour (Kolin and Koutoulakis, 1988). Elastin-rich type of scar 
was more restricted in distribution. In RG-SBCCs the elastic and scar tissue 
was seen mainly around tumour lobules, while in DN-SBCCs and R-SBCCs 
the elastic tissue was seen mainly at the advancing border of lobules. 
Therefore the elastic tissue stain may be of value in differentiating RG-SBCCs 
from R-SBCCs and DN-SBCCs. Fibrosis, hyalinization and stromal spindle 
cells were present in majority of the denovo scar, regrowth and recurrent 
BCCs. All RG-SBCCs and R-SBCCs showed fibrosis, while 86% of the DN-
SBCCs showed the same. Jacobs et al (1982) stated that hyalinisation of the 
stroma and fibrosis were more common in aggressive tumours. In this 
present study hyalinisation and fibrosis was a prominent feature although the 
growth patterns were predominantly nodular. 
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Regardless of the mode of therapy, 0.5 to 14% of BCCs recur (Dixon et al, 
1991). The biological behaviour and management of recurrent BCCs is a 
contentious topic. While some studies have demonstrated that an adequately 
treated recurrent BCC is no more likely to recur than an untreated primary 
tumor (Koplin and Zarem, 1980; Sakura and Calamel, 1979), other studies 
have found significantly higher recurrence rates for these tumors (Taylor and 
Barisoni, 1973; Monballiu, 1968; Menn et al, 1971). In the present study, 
while a nodular subtype predominated in 20/32 (63%) and micronodular and 
infiltrative patterns predominated in 6/32 (19%) recurrent SBCCs, only 3/32 
(9%) lacked at least a minor aggressive or infiltrative component. Coupled 
with these findings, it is controversial whether a recurrent BCC is aggressive 
from the onset or whether it becomes more aggressive with each recurrence. 
Assessment of the initial biopsy of seven R-SBCCs confirmed the conversion 
to more aggressive and less aggressive phenotypes in one case each. In 5/7 
cases, a micronodular or infiltrative pattern was present in initial and second 
tumours. One tumour phenotype changed from predominantly infiltrative in 
BCC1 to predominantly nodular in BCC2. Although the majority of the initial 
and second tumours had a predominant nodular component, it is possible that 
the biologically aggressive nature of the BCC is the function of the minor 
aggressive histologic components. However, it is difficult to ascribe the 
aggressive recurrent nature of the BCCs to the minor components when all 
the initial BCCs were completely excised with adequate margins. Initial and 
second tumors of R-SBCCs were characterized by minor aggressive 
histological subtypes in the majority of cases. The profile of the R-SBCCs 
was similar to that of DN-SBCCS, none of which recurred and similar to the 
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findings of some previous workers, where inadequately treated BCCs did not 
recur (Koplin and Zarem, 1980; Sakura and Calamel, 1979). Why some 
BCCs with aggressive histological subtypes recur and others do not, despite 
adequate excision, remains unexplained and enigmatic. It is tempting to 
speculate that the pathogenetic evolution of the aggressive histological 
subtypes in the different study cohorts differ, resulting in the biological 
heterogeneity despite the shared morphology. It is therefore critical that the 
cellular and stromal factors be investigated, to elucidate the biological profile 
of BCCs within scars, not only for an improved understanding of the 
pathogenesis of R-SBCCs, but also to ensure optimal, including preventitive, 
management of all scar BCCs. At a practical level, despite histological 
confirmation of complete excision with adequate margins, based on the 
behaviour of these tumors, it is still not possible to guarantee complete cure. 
There are no statistically valid guidelines for the management of patients with 
incompletely excised BCCs (Dellon etal, 1985). While the destructive 
potential of regrowth BCCs at sites of incomplete excision is well recorded 
(Sakura and Calamel, 1979; Jackson and Adams, 1973; Mikhail etal, 1977; 
Dvoretsky etal, 1978), re-excision of margin positive BCCs has been 
advocated in some reviews (Koplin and Zarem, 1980). The opposing view is 
that since one third of margin positive BCCs regrow and since regression of 
regrowth BCCs may occur, the BCC site could be observed at regular 
intervals for regrowth (Dellon etal, 1985). In 1985, Dellon etalassessed the 
histopathologic features promoting regrowth of incompletely excised BCCs. 
Their results demonstrated a 95% probability of regrowth if there was more 
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than 75% irregularity of the peripheral palisade of tumor cords or nests. The 
sites of irregularities were hypothesized to be foci of invasion. No degree of 
host lymphocyte response impacted on the regrowth potential. However, in 
tumors with 25-75% irregularities of the peripheral palisade and an absent 
lymphocytic host response, 88% of BCCs regrew. In the presence of a strong 
host response, 25% of BCCs regrew. In the present study, 89% RG-SBCCs 
contained infiltrative and/or micronodular subtypes. Comparison of initial and 
the second regrowth tumours demonstrated infiltrative and/or micronodular 
subtypes in 7/8 cases. Similar to R-SBCCs, the majority of RG-SBCCs had 
extended into the deep dermis and subcutis. The histopathological profile 
was no different from that of DN-SBCCs or R-SBCCs. While the importance 
of identifying an infiltrative component as a predictor of regrowth of 
incompletely excised BCCs was detailed most intensively by Thackray in 
1951, coinage of the term "micronodular" as a distinct subtype, that was 
predictive of regrowth, was detailed about 30 years later by Lang and Maize 
(1986). Similar to the study of these workers and that of several other 
workers, the majority of RG-SBCCs in the present study had aggressive 
micronodular or infiltrative subtypes. However, this study also demonstrates 
that the nodular subtype was the predominant component of all BCCs 
occurring in scars of varied origin. In addition, morphological confirmation of 
the presence of infiltrative and micronodular components as markers of 
aggressive growth appears an oversimplification; Swetter etal (1998) 
demonstrated this in incompletely excised BCCs and the present study 
highlights DN-SBCCs with morphologically aggressive phenotypes that have 
not recurred. While the morphological features may serve as a tocsin for 
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possible regrowth, the gold standard for management guidelines must still be 
multifaceted, and individualized. 
From a histopathological perspective, SBCCs are characterized by a range of 
histopathological subtypes. While aggressive micronodularand infiltrative 
subtypes occurred in 79/81 biopsies, the majority contained a nodular 
subtype. BCCs containing these aggressive morphologic, albeit minor, 
subtypes within iatrogenic and non-iatrogenic induced scars require further 
profiling of biological markers to determine their true biological potential. 
Epithelial proliferation markers and cell cycle status, and stromal basement 
membrane and cellular characteristics may hold clues to the true aggressive 
versus non-aggressive nature of SBCCs with aggressive histological 
subtypes. 
In the present study de novo scar BCCs (DN-SBCCs) which were induced by 
burns, trauma (biopsy scar), vaccinations, as well as tattooing were re-
appraised. BCCs that were incompletely excised and regrew (RG-SBCCs), 
as well as BCCs that were completely excised and recurred (R-SBCCs) 
formed cohorts that occurred in iatrogenic scars. In 1986, Lang and Maize 
chose to study recurrent basal cell carcinomas to determine whether these 
BCCs become biologically more active with each recurrence or whether these 
BCCs have aggressive histopathologic features in the original lesions. They 
concluded that most of the recurrent tumours are aggressive from the very 
beginning. It has also been stated that BCCs that regrow at sites of 
previously incomplete excision have an infiltrative pattern and therefore mimic 
aggressive BCCs. Scar formation appears to cause changes in connective 
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tissue stroma that may play a role in subsequent BCC growth (Swetter et al, 
1998). The possibility is that BCCs track along collagen and fibrous tissue 
produced by scar formation and simulates an aggressive growth pattern. 
The majority of the DN-SBCCs, RG-SBCCs and R-SBCCs showed a 
predominantly nodular growth pattern, with 11% of the DN-SBCCs and RG-
SBCCs and 10% of R-SBCCs having predominantly infiltrative patterns. 
Although 63% of RG-SBCCS had a predominantly nodular growth pattern and 
60% of R-SBCCs showed same, 33% RG-SBCCs showed minor infiltrative 
growth patterns and 40% R-SBCCs showed minor infiltrative patterns. The 
nodular BCCs showed palisade formation and demonstrated smooth rounded 
contours, therefore demonstrating a non-aggressive architectural appearance. 
The infiltrative BCCs had spindle shaped basaloid cells with no palisade 
formation. Jacobs et al (1982) hypothesised aggressive behaviour in BCCs 
with an infiltrating pattern. 
Perineurial invasion was not significantly different in the 3 groups. Three 
(10%) DN-SBCCs, 7 (26%) RG-SBCCs and 6 (24%) R-SBCCs showed 
perineurial invasion. Perineurial invasion was seen in BCCs from the head 
and neck area, except for one BCC that was from the chest wall. 
5.2 Immunohistochemical features of S-BCCs 
5.2.1 bcl-2 
bcl-2 was discovered adjacent to the breakpoints of a chromosome 
rearrangement which is commonly seen in B-celi lymphomas. bcl-2 was 
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cloned more than a decade ago, but its unique characteristics have become 
evident only relatively recently (Tsujimoto et al, 1986). The bcl-2 proto-
oncogene encodes for a 24-kd protein expressed in the nuclear envelope, 
endoplasmic reticulum and mitochondrial membranes. The exact mechanism 
of action of bcl-2 is not known but high expression of bcl-2 is associated with 
cell longevity through reduced apoptosis. bcl-2 promotes cell survival even in 
the absence of a high rate of cell proliferation, thus providing a growth 
advantage that may eventually lead to neoplastic transformation (Cerroni and 
Kerl, 1994). The relationship between the prognosis of solid tumours and bcl-
2 expression has not been fully elucidated. Although bcl-2 positive tumours 
may have a better prognosis than bcl-2 negative tumours, exceptions have 
been described, wherein some carcinomas demonstrated a better prognosis 
despite showing low bcl-2 positivity (Colombel et al, 1993; Pezzella etal, 
1993; Chetty R etal, 1997). While Nakagawa et a/(1994) reported bcl-2 
immunopositivity in 67% of BCCs, other studies have reported staining in 
100% of BCCs (Mooney et al, 1995; Morales-Ducret et al, 1995; Verhaegh et 
al, 1995). High levels of bcl-2 immunostaining in non-aggressive BCCs has 
also been described by several other workers (Morales-Ducret etal, 1995; 
Verhaegh etal, 1995; Crowson etal, 1996; Wikonkal etal, 1997). High bcl-2 
expression was a manifestation of all non-aggressive BCC subtypes, while 
low bcl-2 expression, was a statistically significant marker of aggressiveness 
(Ramdialefa/,2000). 
In 1996, Crowson et al investigated bcl-2 immunoexpression in different 
histologic subtypes of BCCs. They found that aggressive histologic subtypes, 
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such as the infiltrative metatypical and morphoeic BCCs, showed less bcl-2 
immunostaining, than did the superficial and circumscribed BCCs. Ramaili 
(MMed Sci Thesis, University of KwaZulu-Natal, 2000) revealed that there 
was reduced expression of bcl-2 in the infiltrative component of non-
aggressive BCCs, implying that cells had less protection from apoptotic death. 
Therefore despite high MIB-1 labelled cells, cells with damaged DNA will not 
survive and will be eliminated through apoptosis in the presence of low bcl-2, 
resulting in the reduction of tumour volume. 
Ramdial (MMed Thesis, University of KwaZulu-Natal, 1999) suggested that 
the proliferation of neoplastic cells in BCCs may be due to protection from 
apoptosis that is mediated by aberrant persistence of high levels of bcl-2 
protein. However, similar to the findings of Cerroni and Kerl (1994) and 
Ramdial (MMed Thesis, University of Natal, 1999) the occurrence of high bcl-2 
immunopositivity in association with a high apoptotic count in the BCCs 
studied, is unexplained. Factors such as apoptosis and mitotic activity, do not 
appear influential, since there was no statistically significant difference in the 
apoptotic and mitotic indices in the aggressive and non-aggressive BCCs. 
The majority (>70%) of the DN-SBCCs in the present study that showed high 
(>2+) bcl-2 immunopositivity had a predominantly nodular growth pattern with 
minor superficial, micronodular and infiltrative patterns. The minority (<30%) 
of cases displayed low (<2+) bcl-2 immunostaining. Only 1 initial biopsy of 
both RG-SBCC and R-SBCC showed low (<2+) bcl-2 immunopositivity and 
the predominant growth pattern in these biopsies were of an infiltrative nature. 
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Of the 17% of DN-SBCCs that showed low (<2+) bcl-2 immunopositivity, 10% 
had a predominantly nodular growth pattern with minor superficial, 
micronodularand infiltrative patterns, while 7% had a predominant infiltrative 
growth pattern. Twenty six percent of the RG-SBCCs and 28% of the R-
SBCCs showed low (<2+) bcl-2 immunopositivity. Of the 26% of RG-SBCCs 
that showed low (^2+) bcl-2 immunopositivity, 11% had a predominantly 
infiltrative or micronodular pattern, while the other 15% had a predominantly 
nodular growth pattern with minor superficial, micronodular and infiltrative 
patterns. Twelve percent of R-SBCCs that showed low (^2+) bcl-2 staining 
had a predominantly infiltrative growth pattern with minor superficial, nodular 
and micronodular growth patterns, while the other 16% had predominantly 
nodular growth patterns with minor superficial, micronodular and infiltrative 
patterns. Although bcl-2 staining was noted in all DN-SBCCs in the above 
study, it was similar to that reported by Ramdial era/(2000), wherein all non-
aggressive BCCs showed high (>2+) bcl-2 immunostaining, while the majority 
of the aggressive BCCs showed low (^2+) bcl-2 immunostaining. High bcl-2 
immunostaining in non-aggressive BCCs has also been described by several 
other workers (Morales-Ducret etal, 1995; Verhaegh etal, 1995; Crowson et 
al, 1996; Wikonkal etal, 1997). Although DN-SBCCs were characterized by 
infiltrative histological features, the high bcl-2 immunopositivity of DN-SBCCs 
in the present study is indicative of a non-aggressive phenotype. These 
BCCs mimic aggressive BCCs by showing infiltrative growth patterns, 
possibly due to the BCCs tracking along collagen and fibrous tissue produced 
by scar formation, simulating an aggressive growth pattern. 
CHAPTER 5 102 
5.2.2 MIB1 
Cell proliferation characteristics are a fundamental biological determinant of 
the behaviour of many tumour types (Tubiana and Courdi, 1987; Kanatakis et 
al, 1997). Tumour growth is determined by a combination of cell cycle time 
for each tumour cell (the growth fraction) and balance between cell production 
and cell loss. A range of MIB1 expression has been described in the different 
histologic subtypes of BCC (Baum et al 1993; Healy et al 1995; Horlock et al 
1998). Healy et al (1995), found a higher growth fraction in BCC which 
recurred after complete excision. In the present study on scar BCCs, the 
initial and recurrent biopsies were similar in that both showed low MIB1 
immunoposivity. The initial and regrowth biopsies in the present study which 
had minor micronodular growth patterns also showed low MIB1 
immunopositivity. This is similar to the study by Horlock et al (1998), wherein 
micronodular BCCs, also prone to incomplete excision and subsequent 
recurrence, were characterized by a relatively low growth fraction. Ramiali 
(MMed Sci Thesis, University of KwaZulu-Natal 2000) demonstrated high 
MIB-1 staining in micronodular BCCs. One of the reasons postulated for the 
high MIB-1 staining in micronodular BCCs was that micronodular aggregates 
are usually present at the tumour/stromal interface, where adequate 
oxygenation is present, rather than centrally, where the vascular supply is 
reduced. Horlock et al (1998) found a lower MIB1 growth fraction in 
micronodular and nodular BCCs in comparison to tumours with a morphoeic 
or infiltrative pattern of growth. Horlock et al (1998), in their study of horrifying 
and non-horrifying BCCs found no difference in growth fraction in the tumours 
of similar histological growth patterns. They suggested that infiltrative or 
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nodular tumours of horrifying and non-horrifying tumours are biologically 
similar. Similar to the findings of Horlock et al (1998), the study on aggressive 
and non-aggressive BCCs subtypes (Ramdial MMed Thesis, University of 
KwaZulu-Natal, 1999) demonstrated no significant differences. The majority 
(>80%) of the scar BCCs in the present study showed low (<2+) MIB1 
immunopositivity in a variety of BCC subtypes. There was no definite MIB1 
qualitative or quantitative staining patterns noted in different scar BCCs. 
MIB1 staining was random central and peripheral in all tumours; there was no 
defined spatial distribution. Similar staining in all subtypes implies that cell 
proliferation alone does not account for growth patterns of DN-SBCCs. Baum 
et a/(1993), have claimed that proliferating cells are scattered randomly, 
whereas other investigators have found proliferative activity predominantly in 
the peripheral cells of BCC strands, especially in the palisaded array (Baum et 
al, 1993). In the study by Baum et al (1993) a peripheral and a random 
distribution of MIB1 positive cells in BCCs of the nodular and superficial type 
was described. 
5.2.3 p53 
Damage to the genome, occurring during the Gi phase of the cell cycle, 
causes rapid cell arrest which is driven by wild type p53 protein, the levels of 
which rise rapidly within 30 minutes of DNA damage (Kastan et al, 1991). 
The high levels of p53 protein, induced in response to DNA damage, can be 
detected immunohistochemically. The p53 block occurs in the Gi and G2/M 
phases of the cell cycle; this delays progression into the cell cycle, until 
damage is repaired or cells are mobilized into the apoptotic pathway. In 
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addition, a p21 -induced Gi block can either hold cells in G-i, thereby delaying 
the cell cycle or reverts cells back into the Go quiescent stage. The end result 
of both pathways is the reduction of cell numbers and tumour size. The study 
by De Rosa et al (1993) of p53 protein in aggressive and non-aggressive 
BCCs revealed that aggressive BCCs have a higher p53 immunolabeling than 
non-aggressive BCCs, findings similar to that of Ramaili (MMed Sci Thesis, 
University of KwaZulu-Natal, 2000). Shea et al (1992) documented p53 
staining in 83% of the BCCs of the head and neck region. Therefore, high 
levels of p53 might be an indicator of increased aggressiveness of tumour 
cells and an indicator of dedifferentiation. At the point of infiltration, p53 
staining was lower than the dominant nodular component in 23 and the same 
in 27 infiltrative non-aggressive BCCs Ramaili (MMed Sci Thesis, University 
of KwaZulu-Natal, 2000). In the infiltrative front, at the tumour/stromal 
interface, there was high staining. In the deeper free-lying, aggregates in the 
dermis, p53 staining was decreased. Although a range of p53 
immunostaining was noted in all subtypes of non-aggressive BCCs (Ramdial 
MMed Thesis, University of KwaZulu-Natal, 1999), 80% revealed >2+ p53 
immunopositivity. All superficial BCCs showed p53 immunopositivity. The 
p53 immunoprofile of micronodular BCCs was similar to that of the other non-
aggressive subtypes indicating that p53 mutation is not an important driving 
force behind the deeply invasive characteristics of the BCC subtype. Low 
(<2+) p53 immunostaining emerged as a statistically significant predictor of 
aggressiveness (Ramdial MMed Thesis, University of KwaZulu-Natal, 1999). 
In this study, 23/25 aggressive BCCs revealed low (<2+) p53 
immunopositivity, unlike the non-aggressive BCCs, in which high (>2+) 
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immunostaining was prominent. Although the percentage of p53 
immunostaining in the aggressive and non-aggressive BCCs ranged from 
<5% to 100%, the reason why the aggressive cohort of BCCs had low (^2+) 
immunoexpression is uncertain (Ramdial, MMed Thesis, University of 
KwaZulu-Natal, 1999). Other factors that require assessment, in view of the 
present study, include suboptimal p53 staining methodology, or that the 
mutational event in the aggressive cohort was not identified by the antibody 
used. p53 staining difficulties in the tissue sections had necessitated heat-
assisted pressure cooker antigen retrieval; hence other factors might have 
contributed to the results. In the study of Barrett et al (1997) an equal number 
of superficial BCCs displayed low (5-20%) or no p53 immunostaining. An 
intriguing aspect of the study by Barrett et al (1997) is that the histologically 
aggressive subtypes of BCC (sclerosing, infiltrative and metatypical) revealed 
high (>2+) p53 immunopositivity. The study of De Rosa et al, (1993) of p53 
protein in aggressive and non-aggressive BCCs revealed that aggressive 
BCCs have a higher p53 immunolabeling than non-aggressive BCCs. 
In the present study, there was no significant difference in p53 
immunopositivity in scar BCCs. This is similar to the findings of Healy et al 
(1995) who reported an absence of significant differences in p53 
immunopositivity in non-recurrent BCCs, in primary BCCs which later recurred 
and in recurrent BCCs. p53 immunopositive nuclei were randomly distributed 
in the different growth patterns. The immunopositive signal varied from pale 
to bright. The brightest signals were consistently found in the superficial and 
nodular growth patterns. Low and pale staining was mainly seen in the 
infiltrative components. In the present study, 17/29 (59%), 16/27 (59%) and 
CHAPTER 5 106 
13/25 (52%) of DN-SBCCs, RG-SBCCs and R-SBCCs, respectively, 
demonstrated low (<2+) p53 staining. According to that described by several 
workers (Shea etal, 1992; De Rosa et al, 1993; Barrett et al, 1997) these 
would signify BCCs with a non-aggressive immunophenotype. 
Seventeen of 29 DN-SBCCs had low p53 immunostaining. Of 12 with a high 
p53 score, 11 had a predominant nodular histological subtype and one a 
predominant micronodular. All but one had a minor infiltrative subtype. If the 
high p53 score is hypothesized to be a marker of aggressiveness (Shea et al, 
1992; De Rosa etal, 1993; Barrett etal, 1997), the high score is incongruent 
with the non-aggressive clinical outcome and the predominant nodular 
subtype which is associated with a good outcome. Three of these 11 DN-
SBCCs with a high overall p53 score demonstrated a low bcl-2 score in the 
infiltrative component. Eight of these 11 DN-SBCCs demonstrated high bcl-2 
scores in the predominant nodular and minor infiltrative components, 
indicating a non-aggressive phenotype, from a bcl-2 perspective. 
Furthermore, only 4 of the 11 DN-SBCCs with a minor infiltrative component, 
had high p53 staining in the nodular and infiltrative components. Another 
interesting comparison is that, of five with intra-epithelial actin 
immunopositivity, three had high p53 immunostaining, this was accentuated in 
some of the infiltrative foci. These three BCCs also had low bcl-2 scores. 
This combination of staining may also be a signal of heightened potential and 
tumour "preparation" for stromal invasion. The intra-epithelial actin 
immunopositivity in the infiltrative foci may be indicative of an altered 
immunophenotype in preparation for the tumour invasiveness, prior to BM 
disruption, as the laminin was still intact. 
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Eleven of 27 RG SBCCs had a high p53 score, of which 9 had a dominant 
nodular phenotype and two had a predominant infiltrative phenotype. All of 
nine predominant nodular growth patterns had minor infiltrative patterns, while 
two that had a predominant infiltrative pattern had minor nodular histological 
patterns. One with a predominant nodular phenotype had a low bcl-2 score, 
while one with a predominant infiltrative component was accompanied by a 
low bcl-2 score and intra-epithelial and stromal actin immunopositivity. While 
this combination of p53, actin and bcl-2 staining is indicative of an aggressive 
BCC, three RG-SBCCs with a low p53 score of "0" had a high bcl-2 score and 
focal epithelial actin immunopositivity. The difference in this setting probably 
lies in the specific staining within the infiltrative foci. Of the eleven RG-SBCCs 
with high p53 staining, 4 had high p53 staining in the infiltrative component. 
The bcl-2 score within the infiltrative component was low in one case and high 
in the rest. The case with the high p53 and low bcl-2 scores, also had 
intraepithelial and stromal actin immunopositivity indicating that one of the 11 
RG-SBCCs with high p53 staining is a truly aggressive immunophenotype, 
while the others were developing/evolving an aggressive immunophenotype. 
Thirteen of 25 R-SBCCs had low p53 immunostaining. Twelve of 25 R-
SBCCs had a high p53 score, of which seven had a predominant nodular 
histological subtype, with minor infiltrative and micronodular patterns in five 
and a superficial pattern in two. Four had a predominant infiltrative with minor 
nodular and micronodular patterns and one a predominant micronodular with 
minor nodular histological subtypes. Two R-SBCCs with a high p53 score 
had a low bcl-2 score. While both had predominant infiltrative growth 
patterns, one of these R-SBCCs had 2+ laminin discontinuity. One R-SBCC 
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with intra-epithelial actin immunopositivity, had increased p53 
immunopositivity staining with a predominant infiltrative growth pattern, but a 
high bcl-2 score. 
The p53 findings in the present study cannot be used as a predictor of 
aggressive potential. However, the literature in general, has a range of p53 
results, including reports in which no p53 staining was present. As differing 
methodologies were used in the local departmental studies, and may be 
important in the outcome of the local, so too, the use of different antibodies, 
frozen versus formalin-fixed tissue and staining techniques may be 
responsible for the disparate results. 
• Although a range of p53 immunostaining was noted in all subtypes of 
non-aggressive BCCs, 80% revealed >2+ p53 immunopositivity 
(Ramdial, MMed Thesis, University of KwaZulu-Natal, 1999). 
• In the study of Barret et al (1997), an equal number of superficial BCCs 
displayed low (5-20%) or no p53 immunostaining. 
• It could be speculated that from Ramaili (MMed Sci Thesis, University 
of KwaZulu-Natal, 2000), high expression of p53 correlates with 
aggressiveness of micronodular BCCs. Results of this study showed 
that micronodular BCCs not only demonstrated high p53 but also low 
bcl-2. 
• In one study of Moles et al (1993), p53 immunopositive was found in 
48% of BCCs, suggesting that p53 mutations had occurred. 
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What does emerge, however, is that the infiltrative foci of scar BCCs are 
characterised by immuno-phenotypic heterogeneity. The majority have a non-
aggressive immunophenotype. The use of laminin, muscle specific actin and 
bcl-2 are important prognostic markers. Laminin discontinuity, intra-epithelial 
and/or stromal actin, and low bcl-2 immunopositivity potentially indicate an 
aggressive immunophenotype. RG-SBCCs with any of the above marker 
profiles should be subjected to adequate complete re-excision, rather than 
adoption of a wait-and-see policy. p53 does not appear to play a reproducible 
prognostic role, but high staining may be an alarm bell. 
5.2.4 Fibronectin 
Fibronectin plays a major role in cell adhesion and migration, maintenance of 
normal cell morphology, cytoskeletal organisation, haemostasis, cell 
differentiation and oncogenic transformation. In the present study, the 
majority of the scar BCCs showed low (<2+) fibronectin immunopositivity. 
DN-SBCCs and R-SBCCs showed low (<2+) fibronectin immunopositivity in 
76%, while 52% of RG-SBCCs showed low (<2+). In a previous study 
(Ramdial, MMed Thesis, University of KwaZulu-Natal, 1999) on aggressive 
and non-aggressive BCCs, 60% of non-aggressive BCCs did not reveal 
peritumoural fibronectin immunopositivity and 40% revealed 1 + peritumoural 
fibronectin immunopositivity. De Rosa et al (1994), in their study of 
aggressive and non-aggressive BCCs, found that 18/19 aggressive BCCs 
revealed diffuse granular or fibrillar peritumoural fibronectin positivity, which 
was similar to Ramdial (MMed Thesis, University of KwaZulu-Natal,1999), 
wherein peritumoural fibronectin immunopositivity was present in 88% of the 
CHAPTER 5 110 
aggressive BCCs, but was not a prominent feature of any non-aggressive 
BCCs. DeRosa et al (1994) did not suggest a reason for the negative staining 
in one aggressive BCC. In their study, De Rosa et al (1994) demonstrated 
absence of peritumoural fibronectin immunopositivity in 16/19 non-aggressive 
BCCs. The present study showed low (<2+) fibronectin immunopositivity in 
68% of the scar BCCs, indicating alignment to a non-aggressive BCC growth 
profile. Twenty four percent of DN-SBCCs and R-SBCCs that showed high 
(>2+) fibronectin immunopositivity had a predominantly nodular growth 
pattern. Nelson et al (1983) also reported intense peritumoural fibronectin 
immunopositivity in 7/7 non-aggressive BCCs. The presence of fibronectin in 
all cases is hypothesised to be a function of the peritumoural scarring 
process. Being a prominent matrix component, fibronectin plays important 
roles in various stages of wound healing (Brown et al, 1993) and during tissue 
re-modelling in atherosclerosis, pulmonary fibrosis and glomerulosclerosis 
(Kosmehl et al, 1996). Furthermore, it is a marker of angiogenesis in 
neoplastic and non-neoplastic conditions (Kosmehl et al, 1996). The exact 
significance of 4+ fibronectin staining in two DN-SBCCs is intriguing. 
Comparison of other markers reveals low (2+) bcl-2 staining, intact laminin, 2+ 
MIB1 scoring and 3+ or 4+ p53 staining. While the MIB1 had a 2+ score in 
the tumours, there was higher staining in the infiltrative foci. It is therefore 
interpreted that the high fibronectin is a function of scarring plus a more 
aggressive biology, especially in view of the low bcl-2 staining and high p53 
staining. Four RG-SBCCs and 3 R-SBCCs had 4+ fibronectin staining. One 
RG-SBCC had a predominantly infiltrative morphology, a bcl-2 score of 1 +, 
p53 score of 4+, MIB1 of 1+ and intact BM laminin. Two of the RG-SBCCs 
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had a bcl-2 score of 2+, one of which had a predominant infiltrative and the 
other, predominant micronodular pattern. The MIB1 scores were 2+ and p53 
was 4+ and 1+. One demonstrated 2+ laminin discontinuity, while the other 
demonstrated intact laminin staining. The fourth RG-SBCC with high 
fibronectin staining had a predominant nodular and minor micronodular, 
superficial, infiltrative patterns and demonstrated 2+ laminin loss in the 
infiltrative component, p53 of 3+, and a bcl-2 score of 2+. All of the RG-
SBCCs with 4+ fibronectin staining had an aggressive immunoprofile in the 
proliferation and other stromal markers. 
Three R-SBCCs had a fibronectin score of 4+. One had a predominant 
infiltrative pattern, a p53 of 3+, bcl-2 score of 1 + and 2+ laminin loss. Two had 
a predominant nodular morphology, minor micronodular or a combination of 
superficial, micronodular and infiltrative patterns. While both R-SBCCs had a 
bcl-2 score of 1+, the laminin profile varied but p53 scores were high. The R-
SBCCs with a nodular/micronodular subtype demonstrated intact laminin and a 
p53 score of 3+, while that with a nodular/micronodular/superficial/infiltrative 
combination demonstrated 2+ laminin discontinuity and p53 score of 3+. 
Hence, whilst the presence of fibronectin in the stroma of the scar BCCs is 
hypothesised to be a function of scarring process, 4+ staining is accompanied 
by low bcl-2 and high p53 staining is hypothesised to portend an aggressive 
immunophenotype. That the BM laminin was intact in 4 cases suggests that 
laminin disruption is a later event in the evolution of an aggressive infiltrative 
component in BCCs. 
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5.2.5 Laminin 
Basement membranes (BMs) are ubiquitous structural components of the 
extracellular matrix of normal and neoplastic tissues (Damjanov, 1990). 
Ultrastructurally basement membranes are characterised by the presence of 
basal laminae, which are further subdivided into a lamina densa and lamina 
lucida (Vracko, 1974). The former consists of tightly matted randomly 
orientated fibrils 3-4nm in diameter, embedded in a dense matrix. The 
principal constituents of basal lamina are type IV collagen, the high molecular 
weight glycoprotein, laminin, and proteoglycans (Timpl etal, 1979; Timpl etal, 
1981; Poole, 1986). Although originally considered to be an inert framework 
for cells or for delineating parenchymal and stromal tissue compartments 
(Stenback etal, 1985; Vracko, 1974), the basement membrane is now known 
to be involved in the maintenance of organ integrity and to participate in their 
specialised functions (Gorstein, 1988). BMs form a barrier to the passage of 
macromolecules from the blood, serve as substratum for attachment of 
endothelial and epithelial cells and contribute to the differentiation of tissue 
(Stenback et al, 1985). Similar to resident cells of an organ, the neoplastic 
cells, stromal cells or both may produce various BM components and even 
assemble complete BM (Liotta, 1986; Martinez-Hernandez and Amenta, 
1983). Although benign tumors form BMs that are structurally and functionally 
indistinguishable from those in normal adult tissues, in malignant tumours, the 
BM is defective. In such tumors, it is debatable whether the tumor produces 
defective or destroys basement membrane. Invasion and metastasis are 
hallmarks of malignant neoplasia and frequently determine the course of the 
disease (Havenith etal, 1987). In carcinomas, a dynamic interaction occurs 
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at the interface between tumor cells and the surrounding mesenchymal 
stroma. 
In the present study, the majority of scar BCCs (91%) showed intact 
basement membrane laminin staining around the tumour aggregates and the 
rest displayed 1+, 2+ or 3+ basement membrane discontinuity. The initial 
biopsies and regrowth and recurrent SBCCs demonstrated intact basement 
membrane laminin staining. The scar BCCs that showed 2+ (6%) laminin 
discontinuity had a predominant nodular growth pattern with minor superficial 
and micronodular patterns, as well as the presence of a lymphocytic infiltrate 
at the tumour stroma interface. Micronodular BCCs has been described as a 
histologically aggressive subtype (Lang and Maize, 1986). However, in the 
present study, although the invasive nature of the micronodular subtype was 
confirmed, the laminin staining was continuous. One RG-SBCC that showed 
3+ laminin discontinuity had a predominant nodular growth pattern, while the 
other two RG-SBCCs that showed 2+ basement membrane laminin 
discontinuity had a predominant nodular growth pattern in one and an 
infiltrative growth pattern in the other with minor superficial, nodular and 
micronodular patterns. These did not contain a lymphocytic host response at 
the tumour stroma. Instead they were intimately apposed to scar tissue and a 
myofibroblastic response. Although DN-SBCCs have shown infiltrative growth 
patterns with the presence of spindle shaped cells, resembling those of the 
aggressive BCC subtype, the basement membrane laminin staining pattern is 
continuous. Nine percent of scar BCCs that demonstrated discontinuous 
laminin staining contained a host lymphocytic infiltrate at the tumour-stroma 
interface. These findings were similar to the findings in the study of non-
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aggressive BCCs (Ramdial, MMed Thesis, University of KwaZulu-Natal, 1999) 
wherein 56% of tumours that demonstrated laminin discontinuity contained a 
host tumour-stroma lymphocytic infiltrate. Some workers have reported 
continuous basement membrane around BCC islands in non-aggressive 
BCCs (Nelson etal, 1983; Barsky etal, 1987; De Rosa era/, 1994), while 
others have found modifications in the distribution of basement membrane in 
the different histological subtypes of BCCs. Kallionen et al (1984) reported 
continuous basement membrane around tumour aggregates of non-sclerosing 
BCCs. Van Cauwenberge (1983) made a similar observation, but their 
studies were unrelated to clinical behaviour, recurrence rates or metastases. 
Why some non-aggressive BCCs manifested laminin discontinuity while 
others did not, is not known. In the study by De Rosa et al (1994), the cause 
of the laminin discontinuity in 2/19 non-aggressive BCCs was not addressed. 
Barsky et al (1983), in their study of invasive tumours, stated that loss of 
basement membrane components is associated with invasion. They also 
stated that while many epithelial lesions may mimic the appearance of 
invasion, histologically, these lesions demonstrate intact basement membrane 
components. D'Ardenne (1989) stated that breaks in basement membrane at 
sites of inflammation are small and sharply defined in contrast to the irregular 
discontinuities found in in-situ carcinoma. Others have suggested that the 
gaps in basement seen in dysplasia may be due to enzymes produced by 
inflammatory cells and this might promote invasion (D'Ardenne, 1989). High 
levels of typel collagenase have been described in BCCs. Such high levels 
of typel collagenases, derived from stromal fibroblasts that surround epithelial 
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islands of basal cells, are purported to be a characteristic of stromal modelling 
by activated fibroblasts. Typel collagenases are known to degrade basement 
membranes. It is therefore tempting to speculate that stromal factors are 
responsible for basement membrane degradation, and BCCs with an 
infiltrative phenotype and basement membrane laminin loss in the absence of 
a host lymphocytic response at the tumour-stroma interface, represent 
biologically aggressive infiltrative foci in scar BCCs. 
5.2.6 Actin, Desmin and Vimentin 
Actin is a highly conserved ubiquitous, microfilamentous, cytoskeletal protein. 
Although it normally exists in large amounts in muscle, it is known to exist in 
non-muscle cells. Different cell types contain immunochemically distinct 
actins that vary in sequence and iso-electric point. While skeletal, cardiac and 
vascular smooth muscle each contain unique a-actins, non-muscle cells 
contain actins of (3 and y motility. The presence of distinct actin isotypes in 
muscle cells suggest that some actin variants are specifically tailored for cell 
contraction. An increase in contractile proteins and a relationship with cell 
movement in epithelial cells during reactive and neoplastic processes has 
been described (Low etal, 1981; Pollard and Weihing, 1974). The presence 
of these contractile proteins in human cancer cells has been studied by 
means of immunofluorescence staining using anti-actin antibodies, and, by 
ultrastructural demonstration of cytoplasmic microfilaments. The presence of 
these microfilaments was related to enhanced motility of invasive carcinoma 
cells. Strong peripheral actin immunofluoresence has been described in the 
invasive component of malignant cells that ultrastructurally reveal 
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pseudopodlike protrusions and contain a well developed microfilamentous 
network. In addition, actin immunopositivity has been described in 
myofibroblasts, which are an integral component of the desmoplastic stroma 
of malignant tumours. Since 1980, several monoclonal and polyclonal 
antibodies to actin isotypes have been described. Tsukada et a/(1987) 
generated an actin antibody, HHF35, which detects an epitope common to the 
a and y actin of isotypes of all muscle cells. In addition, HHF35 antibody also 
localizes to myoepithelium, myofibroblasts, reactive mesothelial and 
submesothelial cells and in cells of adenomas and carcinomas of salivary 
gland origin. In malignant tumours, actin expression has paralleled that 
described in normal tissue. In mesenchymal tumours, actin immunopositivity 
is reflective of tumour lineage. In carcinomas, however, actin 
immunopositivity has been described, not only in the desmoplastic stromal 
response but also in the malignant epithelial component (Bertheim et al, 
2004). In carcinomas, ultrastructural demonstration of pseudopodlike 
cytoplasmic protrusions with a well developed microfilamentous network, in 
the periphery and advancing edge of the tumour have been described. The 
periphery of these cells have also displayed strong positivity after 
immunofluorescence staining with actin antibodies. In cutaneous BCCs, 
immunofluorescent intracytoplasmic actin immunopositivity has been 
described, in addition to ultrastructural localization of actin as a 
microfilamentous network. The role of actin immunohistochemical labelling as 
a marker of aggressiveness in basal cell carcinomas has been described in 
terms of peritumoural stromal myofibroblastic actin immunopositivity. 
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However, the value of intracytoplasmic actin immunopositivity, as a predictor 
of aggressiveness has not been described before. 
While it is accepted that tumours are dependent on their surrounding stroma, 
the exact relationship has been insufficiently characterized (Bertheim et al, 
2004). The stroma, or matrix, is made up of a ground substance that is 
composed of glycosaminoglycans containing a complex meshwork of 
collagen, fibronectin and elastin (Moy et al, 2000). It has been hypothesised 
that tumour pathogenesis, progression and metastases may be caused by 
tumour cell interaction with its extracellular stroma (Parrott et al, 2001). 
Myofibroblasts, which have been investigated extensively in the stroma of 
carcinomas of the breast, are also a common finding in the stroma of primary 
invasive carcinomas in various extra-mammary sites and in metastatic 
carcinomas. Myofibroblasts are not a normal constituent of the skin, but their 
presence in skin tumours are indicative of a stromal response to neoplasia. In 
BCCs, an intimate association between tumour parenchyma and the stroma 
exists. Experimental and autotransplant studies of BCCs have shown a 
striking growth-related interdependence between the neoplastic cells and 
stroma (Kirkham, 1997). Seemayer et a/(1980) have hypothesised that the 
myofibroblastic reaction is an expression of a non-immune stromal response 
to neoplasia and serves to retard or contain the growth of the malignant 
cellular population. The density and contractile state of such tissue is 
hypothesised to limit the mobility and accessibility of tumour cells to vascular 
channels or perineural spaces. Schurch et al (1998) have, however, 
suggested that the myofibroblasts within the desmoplastic response secrete 
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enzymes that degrade the extracellular matrix, facilitating tumour invasion. 
They concluded that carcinomas were not uniform with regard to stromal 
reactions and that even within the same neoplasm, mechanisms co-exist that 
either facilitate or prevent/delay tumour invasion. However, no description 
exists on the actin immunohistochemistry in paraffin wax BCC sections. 
The peritumoural stromal cells in DN-SBCCs in the present study were actin 
and desmin negative, but vimentin immunopositive. The myofibroblasts were 
therefore of "V" immunophenotype. The findings in the present study were 
similar to that of De Rosa et al (1994). In their study of aggressive and non-
aggressive BCCs, all non-aggressive BCCs were actin negative and the 
majority were desmin negative, but ail aggressive BCCs showed actin, focal 
desmin and vimentin immunopositivity. In a similar study to De Rosa et al 
(1994), of aggressive and non-aggressive BCCs, all non-aggressive BCCs 
showed no actin or desmin immunopositivity, while all aggressive BCCs were 
positive for stromal actin (Ramdial, MMed Thesis, University of KwaZulu-
Natal, 1999). Ramdial (MMed Thesis, University of KwaZulu-Natal, 1999) 
concluded that actin immunopositivity in BCCs represents a feature of 
aggressiveness and although the desmoplastic response was also a feature 
of aggressiveness, its exact significance as a promoter of, or barrier to, 
invasion remains unknown. The presence of epithelial actin immunopositivity, 
however, similar to previous studies, may be indicative of the initiation step of 
aggressive behaviour. While the majority of RG-SBCCs and R-SBCCs did 
not demonstrate epithelial or stromal actin immunopositivity, 25% of BCCs in 
both groups demonstrated actin positivity. This was noted either in stromal 
myofibroblasts and/or the focally infiltrative spindle cell epithelial components. 
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Hence, it is hypothesised from this study that the actin immunostaining in DN-
SBCCs highlights the tumours with a biologically aggressive profile or with the 
potential for aggressive growth. Not all DN-SBCCs with a focally infiltrative 
pattern demonstrated actin positivity. In five DN-SBCCs with intact laminin 
and exclusive epithelial actin immunopositivity, it is hypothesised that this is 
the initial event where the epithelial cells are being remodelled for infiltration. 
In RG-SBCCs and R-SBCCs, all those with exclusive epithelial or mixed 
epithelial and stromal actin immunopositivity also demonstrated laminin 
immunopositivity. In these cases, the actin and laminin stains are critical 
markers predictive of aggressive growth in DN-SBCCs with an infiltrative 
pattern. It also serves to highlight the fact that not all RG-BCCs and R-BCCs 
with an infiltrative morphology have an aggressive biological 
immunophenotype. The infiltrative morphology in these tumours is therefore 
hypothesised to be a product of cellular scaffolding along the connective 
tissue planes of the scar. The repeated growth of these purported non-
aggressive BCCs is hypothesised to be a function of tumour occurrence at a 
site that is prone to BCC occurrence. 
CHAPTER 6 
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6.0 CONCLUSION 
Historically, scar cancers have been recognised since 100AD. Originally 
described in burn scars, the term cicatricial or scar cancer of the skin was 
coined in the 1980s to describe a spectrum of cancers occurring in scars and 
chronic ulcerative conditions. The majority of scar cancers are squamous cell 
carcinomas. Basal cell carcinomas are poorly recognised as a form of scar 
cancer. Furthermore, although BCCs are characterised by a spectrum of 
histological subtypes; these are poorly characterised in scar cancers. In the 
late nineties, Swetter et al reported the presence of an infiltrative, pseudo-
aggressive phenotype in incompletely excised nodular BCCs (Swetter et al, 
1998). 
As all the present tumours occurred within scar tissue, tumour growth 
occurred in an altered milieu. As there are recognised aggressive histological 
patterns and stromal features, it is critical that truly aggressive BCC attributes 
be delineated from pseudo-aggressive features. While all but 2 cases 
contained infiltrative and micronodular patterns, the exact significance of the 
histomorphology is multifaceted: 
1. That DN-SBCCs with the infiltrative and micronodular patterns have not 
recurred implies that the histomorphology is a pseudo-aggressive 
pattern. 
2. A similar view could pertain to RG-SBCCs. However, the fact that the 
scar did not cicatrise the incompletely excised BCC implies that the 
histomorphology of RG-BCC may be a potentially more aggressive 
phenotype. 
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3. The recurrence of a completely excised basal cell carcinoma may be 
viewed as a feature of an aggressive tumour, especially when the 
recurrent BCC contains micronodular and infiltrative components. 
However, as most R-SBCCs occurred at head and neck sites that are 
exposed to ultraviolet light, it is also possible that these are simply new 
BCCs occurring within scars in head and neck sites prone to BCCs. 
Furthermore, these R-SBCCs were not destructive tumours. 
At a light microscopic H&E morphological level, none of the above possibilities 
can be proven or disproven and remain mainly rhetorical. However, as 
immunohistochemistry has played a vital role in revealing the biological 
characteristics of many tumours, including BCCs, the profile of stromal and 
proliferation/cell cycle markers are also critical in evaluating the morphological 
characteristics of the S-BCCs: 
1) DN-SBCCs 
While the DN-SBCCs contained infiltrative foci, none of the 
infiltrative foci demonstrated laminin loss; this is a non-aggressive 
feature of BCCs. However, some of the infiltrative foci 
demonstrated intra-epithelial MSA positivity, indicating a 
reorganisation of the intra-epithelial actin network. This is 
hypothesised to be one of the earliest cellular alterations for true 
invasion in BCCs. It is important to note that not all infiltrative foci 
within a single tumour demonstrated intra-epithelial actin 
immunopositivity. Some of these infiltrative foci also demonstrated 
accentuated MIB1 and p53 immunostaining. However, while some 
of the infiltrative foci demonstrated high bcl-2 staining, albeit of 
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variable intensity, indicating a non-aggressive bcl-2 profile, 3/5 DN-
SBCCs with intraepithelial actin immunopositivity, also 
demonstrated low bcl-2 staining and high p53 staining, despite an 
intact laminin pattern. This would immunoprofile 3 DN-SBCCs with 
an aggressive profile of the infiltrative components. 
2) RG-SBCCs 
Of 11 RG-SBCCs with high p53 staining, 4 had high p53 staining in 
the infiltrative component, but only one had a low bcl-2 composite 
score and low bcl-2 score in the infiltrative focus. In addition, these 
infiltrative foci demonstrated intraepithelial MSA positivity and a 
"VA" immunophenotype of the stromal cells, indicating one RG-
SBCC with an established, truly aggressive immunophenotype. 
Those positive with one or more, but not all, aggressive 
immunostains, are hypothesised to be RG-SBCCs 
evolving/developing an aggressive immunophenotype. 
3) R-SBCCs 
Only one R-SBCC, with a predominantly infiltrative pattern, had a 
"full-house" of aggressive immunostaining in the infiltrative foci: low 
bcl-2, high p53, 2+ laminin discontinuity and intra-epithelial and 
stromal MSA positivity. Of significance is that 7 with a predominant 
nodular pattern had a high p53 score of which 5 had high bcl-2 
scores. Hence, while high p53 may be a feature of aggressive 
growth, it is important that this staining be complemented with that 
of bcl-2, laminin and MSA. 
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Hence, SBCCs demonstrate phenotypic and immunophenotypic 
heterogeneity. In relation to aggressive, destructive BCCs, SBCCs 
with laminin discontinuity, intra-epithelial and stromal MSA 
immunopositivity, low bcl-2 and high p53 staining are aggressive; 
complete excision is critical to prevent destructive growth and 
recurrence. However, tumours expressing lower combinations of 
aggressive immunomarkers are hypothesized to be evolving 
aggressive BCCs. While high fibronectin staining had been 
demonstrated as a marker of aggressive BCCs in previous studies, 
high fibronectin staining in SBCCs is not a reliable indicator, as the 
scar tissue contains stromal fibronectin. 
New Protocol for Histopathologists: 
All SBCCs with infiltrative foci should be subjected to 
immunostaining with laminin, bcl-2, MSA and p53, and guidelines to 
surgeons should be modelled on the above findings. 
Guidance to Surgeons: 
Excision with adequate margins should be the minimum 
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APPENDIX A: ANTIGEN RETRIEVAL 
1. Microwave Technique 
• Slides were placed in a thermoresistant plastic coplin jar (50ml) 
filled with 0,01 M buffered sodium citrate solution at pH 6.0 
(appendix). 
• They were then incubated at 85°C for 10 minutes in a H2500 
Microwave Processor (Energy Beam Sciences, Inc., Agawam, 
Massachusetts). 
• The sections were allowed to cool in the coplin jar for 5 minutes. 
2. Enzyme Pretreatment Technique 
a) Laminin: Protease pretreatment 
• The sections were pretreated with protease (0.05% in PBS) for 5 
minutes at room temperature. 
b) Fibronectin: Pronase pretreatment 
• The sections were pretreated with pronase (0.05% in PBS) for 5 
minutes at room temperature. 
APPENDIX B: PREPARATIONS OF SOLUTIONS FOR 
IMMUNOHISTOCHEMISTRY 
a) 0.01 M Sodium Citrate antigen retrieval buffer. 
D 2,94g sodium citrate was dissolved in 950ml of distilled water. 
D 400ul of 1N HCI was added and using distilled water, the volume was 
raised to 1000ml. 
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• The solution was kept at room temperature. 
b) Phosphate buffered saline, pH 7.4 (PBS) 
D 10 tablets of PBS were dissolved in 1000ml of distilled water in a 2 litre 
conical flask. 
• The solutions were stored at room temperature. 
c) 3 % Hydrogen peroxide 
• 3ml of hydrogen peroxide was added to 97ml of distilled water 
• The solution was stored at 4°C. 
d) DAB chromogen solution 
D 20ul of the DAB chromogen was added to 200ul of substrate buffer. 
• This solution was stored at 4°C. 
e) 37mM Ammonium hydroxide (ammoniated water) 
D 2.5ml of 15M ammonium hydroxide solution was added to 950ml of 
distilled water 
D Using distilled water, the volume was raised to 1000ml. 
• The solution was kept at room temperature. 
f) Mayer's haematoxylin 
D Using heat, 1g of haematoxylin was dissolved in 950ml of distilled 
water in a 2 litre flask. 
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D While heating, alum was added and was followed by 0.2g sodium 
iodate. 
D 1g citric acid and 50g chloral hydrate were added. Heating continued 
to allow solution of the mixture. 
• The mixture was cooled and using distilled water, the volume was 
raised to 1000ml. 
• The solution was filtered and stored at room temperature. 
APPENDIX C: Preparation of Poly-L-Lysine slides (SIGMA 
DIAGNOSTICS) 
a Poly-L-Lysine coating solution (50ml) was diluted in 450ml of distilled 
water in a trough. 
• New slides were arranged in a staining rack and submerged in the 
Poly-L-Lysine solution for 5 minutes 
D The rack containing the slides was removed from the solution and 
placed on thick absorbent paper to facilitate drainage of excess 
solution. 
• The subsequent emersions were increased by 30 seconds. 
• The solutions was used to coat a maximum of 12 packets of poly-L-
Lysine slides. 
• The coated slides were allowed to dry at room temperature overnight. 
D The coated slides were packed in boxes, in the order of coating. 
D The coated slides were employed in picking sections for 
immunohistochemical staining. 
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PLATE 1: GROWTH PATTERN 
DN-SBCC: Nodular and infiltrative patterns in fibrotic stroma containing a 
lymphocytic infiltrate. 
PLATE 2: GROWTH 
PATTERN 
DN-SBCC: Nodular and 
infiltrative patterns in fibrotic 
stroma containing a 
lymphocytic infiltrate. 
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PLATE 3: GROWTH PATTERN 
DN-SBCC: Nodular and infiltrative patterns in fibrotic stroma containing a 
lymphocytic infiltrate. 
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PLATE 4: GROWTH PATTERN 
DN-SBCC: Nodular and infiltrative patterns in fibrotic stroma containing a 
lymphocytic infiltrate. 
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PLATE 5: GROWTH PATTERN 
DN-SBCC: Nodular pattern with adenoid differentiation in scar tissue. 
PLATE 6: GROWTH PATTERN 
RG-SBCC: Intradermal regrowth with nodular, micronodular and infiltrative 
patterns in scar tissue containing elastotic material and chronic inflammatory 
cells. 
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PLATE 7: GROWTH PATTERN 
RG-SBCC: Intradermal regrowth with nodular, micronodular and infiltrative 




PLATE 8: GROWTH PATTERN 
RG-SBCC: Intradermal regrowth with nodular, micronodular and infiltrative 
patterns in scar tissue containing elastotic material and chronic inflammatory 
cells. 
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PLATE 9: GROWTH PATTERN 
RG-SBCC from epidermis into scar tissue. 
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PLATE 10: GROWTH PATTERN 
R-SBCC: Nodular, micronodular and infiltrative patterns in scar tissue. 
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PLATE 11: GROWTH PATTERN 
R-SBCC: Nodular, micronodular and infiltrative patterns in scar tissue. 
PLATE 12: GROWTH PATTERN 






infiltrative patterns in 
scar tissue. 
PLATE 14: GROWTH PATTERN 




PLATE 15: LAMININ IMMUNOSTAINING 
DN-SBCC: Superficial pattern with intact laminin staining. 
PLATE 16: LAMININ IMMUNOSTAINING 
DN-SBCC: Nodular pattern with intact basement membrane laminin 
staining. 
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PLATE 17: LAMININ IMMUNOSTAINING 
DN-SBCC: Micronodular pattern with intact basement membrane laminin 
staining. 
PLATE 18: LAMININ IMMUNOSTAINING 
DN-SBCC: Focally infiltrative pattern with intact basement membrane 
laminin. 
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PLATE 19: LAMININ IMMUNOSTAINING 
DN-SBCC with loss of laminin staining in area of lymphocytic infiltration. 
, . 
PLATE 20: LAMININ IMMUNOSTAINING 
DN-SBCC with loss of laminin staining in focus of lymphocytic infiltration anc 
adjacent infiltrative focus with intact laminin. 
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PLATE 21: LAMININ IMMUNOSTAINING 
RG-SBCC: Nodular and infiltrative patterns with intact laminin staining. 
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PLATE 22: LAMININ IMMUNOSTAINING 
RG-SBCC: Micronodular and infiltrative patterns with intact laminin staining 
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PLATE 23: LAMININ IMMUNOSTAINING 
R-SBCC: Intact laminin staining in micronodular and infiltrative components 
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PLATE 24: FIBRONECTIN IMMUNOSTAINING 




' : * , - .TL /1 I£ -
S9 -
'3&*. •* -» 
I . e . 
w*ws 
vf< 
"'* .̂  ; i > 
yH 
aw? ', • .' 
PLATE 25: FIBRONECTIN IMMUNOSTAINING 
DN-SBCC: Low fibronectin staining. 
PLATES 168 
PLATE 26: FIBRONECTIN IMMUNOSTAINING 
DN-SBCC: High, bright fibronectin staining. 
PLATE 27: FIBRONECTIN IMMUNOSTAINING 
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PLATE 28: FIBRONECTIN IMMUNOSTAINING 
RG-SBCC: Pale, high fibronectin staining. 
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PLATE 29: FIBRONECTIN IMMUNOSTAINING 
RG-SBCC: High, bright fibronectin staining. 
PLATES 170 
n 
l •• • i 7 
• * ' J 
PLATE 30: FIBRONECTIN IMMUNOSTAINING 
R-SBCC: Low fibronectin staining. 
PLATE 31: FIBRONECTIN IMMUNOSTAINING 
R-SBCC: Pale, high fibronectin staining. 
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PLATE 32: FIBRONECTIN IMMUNOSTAINING 
R-SBCC: High, bright fibronectin staining. 
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PLATE 33: ACTIN IMMUNOSTAINING 
DN-SBCC: MSA negativity in peritumoral stromal cells. Inbuilt control 
positive. 
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PLATE 34: ACTIN IMMUNOSTAINING 




PLATE 35: ACTIN IMMUNOSTAINING 
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PLATE 36: ACTIN IMMUNOSTAINING 
RG-SBCC: MSA negativity in peritumoral stromal cells. Inbuilt control 
positive. 
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PLATE 37: ACTIN IMMUNOSTAINING 
RG-SBCC: Negative MSA stromal response. In-built control (blood vessel) 
positive. 
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PLATE 38: ACTIN IMMUNOSTAINING 




PLATE 39: ACTIN IMMUNOSTAINING 




PLATE 40: ACTIN IMMUNOSTAINING 
RG-SBCC: MSA immunopositivity in epithelial and stromal components. 
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PLATE 41: ACTIN IMMUNOSTAINING 
R-SBCC: Negative epithelial and stromal response to MSA. 






PLATE 42: ACTIN IMMUNOSTAINING 
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PLATE 43 
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ACTIN IMMUNOSTAINING 
R-SBCC: Exclusive epithelial MSA positivity. 
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PLATE 45: ACTIN IMMUNOSTAINING 
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PLATE 46: DESMIN IMMUNOSTAINING 
DN-SBCC: Negative peritumoral stromal cells. In-built control (skeletal 
muscle) positive. 
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PLATE 47: DESMIN IMMUNOSTAINING 
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PLATE 48: DESMIN IMMUNOSTAINING 
R-SBCC: 
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Desmin negativity in scar tissue. In-b 
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PLATE 49: VIMENTIN IMMUNOSTAINING 
DN-SBCC: Vimentin staining of peritumoral spindle cells. 
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PLATE 50: VIMENTIN IMMUNOSTAINING 
DN-SBCC: Vimentin-positive peritumoral stromal cells. 
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PLATE 51: VIMENTIN IMMUNOSTAINING 
R-SBCC: Vimentin positive peritumoral stromal cells. 
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PLATE 52: VIMENTIN IMMUNOSTAINING 
RG-SBCC: Vimentin staining of peritumoral stromal cellular response. 
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PLATE 53: VIMENTIN IMMUNOSTAINING 
RG-SBCC: Vimentin positivity of peritumoral stromal cells. 
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PLATE 54: VIMENTIN IMMUNOSTAINING 
R-SBCC: Vimentin positive stromal cellular response. 
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PLATE 55: VIMENTIN IMMUNOSTAINING 
RG-SBCC: Peritumoral vimentin positive cells around nodular component. 
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PLATE 56: VIMENTIN IMMUNOSTAINING 
R-SBCC: Vimentin-positive stroma around micronodular and infiltrative 
tumour patterns. 
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PLATE 57: VIMENTIN IMMUNOSTAINING 
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PLATE 58: VIMENTIN IMMUNOSTAINING 
R-SBCC: Vimentin-positive peritumoral stromal cells. 
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PLATE 59: MIB1 IMMUNOSTAINING 
DN-SBCC: Low peripheral and central MIB1 staining. 
PLATE 60: MIB1 IMMUNOSTAINING 
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PLATE 61: M1B1 IMMUNOSTAINING 
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PLATE 62: MIB1 IMMUNOSTAINING 
DN-SBCC: High (3+) peripheral and central MIB1 staining. 
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PLATE 63: MIB1 IMMUNOSTAINING 
DN-SBCC: High (3+) MIB1 staining in infiltrative nests and trabeculae. 
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PLATE 64: MIB1 IMMUNOSTAINING 
R-SBCC: Low MIB1 staining in infiltrative component. 
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PLATE 65: MIB1 IMMUNOSTAINING 
R-SBCC: Low MIB1 staining in infiltrative focus. 
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PLATE 66: MIB1 IMMUNOSTAINING 






PLATE 67: M1B1 IMMUNOSTAINING 
R-SBCC: High MIB1 staining in infiltrative focus. 
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PLATE 68: MIB1 IMMUNOSTAINING 
R-SBCC: High MIB1 staining in superficial pattern. 
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PLATE 69: MIB1 IMMUNOSTAINING 
RG-SBCC: Low (2+) MIB1 staining in nodular and infiltrative focus. 
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PLATE 70: MIB1 IMMUNOSTAINING 
RG-SBCC: Low MIB1 staining in infiltrative component. 
PLATES 192 
PLATE 71: MIB1 IMMUNOSTAINING 
RG-SBCC: LowMIBI staining in infiltrative focus. 
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PLATE 72: MIB1 IMMUNOSTAINING 
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PLATE 73 
RG-SBCC: 
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MIB1 IMMUNOSTAINING 
High MIB1 staining in infiltrative component. 
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High MIB1 staining in nodular component. 
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PLATE 75: MIB1 IMMUNOSTAINING 
RG-SBCC: High MIB1 staining in nodular and infiltrative component 
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PLATE 76: MIB1 IMMUNOSTAINING 
DN-SBCC: Sebaceous glands and hair follicle epithelium: in-built control. 
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PLATE 77: M1B1 IMMUNOSTAINING 
R-SBCC: Basal layer MIB1 positivity in epidermis: in-built control. 
PLATE 78: MIB1 IMMUNOSTAINING 
Nodal + MIB1 positivity: External positive control. 
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PLATE 79: p53 IMMUNOSTAINING 
DN-SBCC: High p53 immunopositivity. 
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PLATE 80: p53 IMMUNOSTAINING 
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PLATE 81: 
DN-SBCC: 
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p53 IMMUNOSTAINING 
High p53 immunopositivity. 
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p53 IMMUNOSTAINING 
High p53 immunopositivity. 
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PLATE 83: p53 IMMUNOSTAINING 
DN-SBCC: Low p53 immunopositivity. 
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PLATE 84: p53 IMMUNOSTAINING 
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PLATE 85: p53 IMMUNOSTAINING 
DN-SBCC: Accentuated p53 immunostaining in infiltrative tongue. 
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PLATE 86: p53 IMMUNOSTAINING 
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PLATE 87: p53 IMMUNOSTAINING 
R-SBCC: High p53 immunopositivity. 
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PLATE 88: p53 IMMUNOSTAINING 
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PLATE 89: p53 IMMUNOSTAINING 
R-SBCC: High p53 immunopositivity. 
PLATE 90: p53 IMMUNOSTAINING 
R-SBCC: Low p53 immunopositivity. 
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PLATE 91: p53 IMMUNOSTAINING 
R-SBCC: Low p53 immunopositivity. 
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PLATE 92: p53 IMMUNOSTAINING 
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PLATE 93: p53 IMMUNOSTAINING 
RG-SBCC: High p53 immunopositivity. 
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PLATE 94: p53 IMMUNOSTAINING 
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PLATE 95: p53 IMMUNOSTAINING 
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PLATE 96: p53 IMMUNOSTAINING 
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PLATE 97: p53 IMMUNOSTAINING 
RG-SBCC: Low p53 immunopositivity. 
PLATE 98: p53 IMMUNOSTAINING 
RG-SBCC: Low p53 immunopositivity. 
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PLATE 99: p53 IMMUNOSTAINING 
Adjacent solar keratotic epidermis: In-built positive control. 
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PLATE 100: bcl-2 IMMUNOSTAINING 
DN-SBCC: High, bright bcl-2 immunopositivity. 
PLATE 101: bcl-2 IMMUNOSTAINING 
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PLATE 102: bcl-2 IMMUNOSTAINING 
DN-SBCC: High, bright bcl-2 immunopositivity. 







PLATE 103: bcl-2 IMMUNOSTAINING 










PLATE 104: bcl-2 IMMUNOSTAINING 
DN-SBCC: High, pale bcl-2 positivity. 
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PLATE 105: bcl-2 IMMUNOSTAINING 




PLATE 106: bcl-2 IMMUNOSTAINING 
DN-SBCC: High, pale bcl-2 positivity. 
PLATE 107: bcl-2 IMMUNOSTAINING 
RG-SBCC: High, bright bcl-2 immunopositivity. 
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PLATE 108: bcl-2 IMMUNOSTAINING 
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PLATE 109: bcl-2 IMMUNOSTAINING 
RG-SBCC: High, pale bcl-2 immunopositivity. 
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PLATE 110: bcl-2 IMMUNOSTAINING 
RG-SBCC: High, bcl-2 immunopositivity. 
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PLATE 111: bcl-2 IMMUNOSTAINING 
RG-SBCC: Low, bcl-2 immunopositivity. 
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PLATE 112: bcl-2 IMMUNOSTAINING 
R-SBCC: High, bright bcl-2 immunopositivity. 
*>#f 
PLATE 113: bcl-2 IMMUNOSTAINING 
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bcl-2 IMMUNOSTAINING 
R-SBCC: High, pale bcl-2 immunopositivity. 
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bcl-2 IMMUNOSTAINING 
R-SBCC: Low, bcl-2 immunopositivity. 
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PLATE 116: bcl-2 IMMUNOSTAINING 
Epidermal downgrowth: bcl-2 positive basal cells. In-built posit 
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PLATE 117: bcl-2 IMMUNOSTAINING 
DN-SBCC: Low bcl-2 immunopositivity. 
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